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INTRODUCTION 
 
 Glycosylation is the process of adding sugar moieties to the proteins or 
lipids enzymatically in order to produce Glycoconjugates such as Glycoproteins 
and Glycolipids. 
 
Glycoproteins and Glycolipids have multiple significant role in cell biology1  
such as Protein folding, Protein stability, Transport of proteins, Cell to cell 
recognition, Cell signaling, Cell membrane integrity and Host defense 
 
Congenital disorders of glycosylation refers to a group of metabolic disorders 
which is due to either deficient or defective glycosylation of glycoproteins or 
glycolipids in the tissue of the patient 2.  
Earlier this disorder was termed as carbohydrate deficient glycoprotein syndrome.
 
 
 Congenital Disorders of Glycosylation (CDG) is a genetic disorder 
transmitted in an Autosomal recessive pattern .The clinical presentation of CDG 
is a broad spectrum from nearly normal condition with mild clinical symptoms to 
serious lethal malfunction of different organ systems.The nervous system, 
Congenital disorders of glycosylation-a genetic disease
Defective genes codes for defective enzymes
Defective enzymes causes defective glycosylation
Defective glycosylaton  leads to defective /deficient glycoconjugates
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intestines and muscles are the most affected systems in this disorder. This group 
of disorder is also known as CDG syndromes. Though CDG has a wide variety of 
clinical presentation, neurological impairment is the predominant symptom in 
many subtypes of CDG 3. 
 
 The first case of CDG was reported by Dr. Jaeken and his colleagues in 
1980. Later in the subsequent years about 100 different types of CDG have been  
identified 3. 
 
 The broad clinical presentation of the CDG challenges physicians in 
diagnosing this disorder. One way of diagnosing this defect is by checking the 
glycosylation pattern of a glycoprotein. Defective glycosylation pattern of the 
glycoprotein gives a clue for the diagnosis of CDG. Transferrin being the widely 
abundant glycoprotein in the serum can be checked for its glycosylation pattern. 
Glycosylation pattern of transferrin was studied by isoelectric focussing 
technique which is the established gold standard technique for the diagnosis of 
CDG. The technique of isoelectric focussing is labour intensive and time 
consuming. Since fast and accurate diagnosis of metabolic disease is very 
essential to provide the best care for the patients, need was felt for other 
automated & rapid techniques to study the glycosylation pattern. This lead to the 
evolution of new techniques4 such as   
 
a. Capillary zone electrophoresis,  
b. Micro-column separation combined with turbidimetry, 
c. High-performance liquid chromatography,  
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d. Radioimmunoassay (RIA) 
e. Enzyme immune assay (EIA) 
f. Electro spray mass spectrometry. 
  
 Among the automated techniques for diagnosing congenital disorders of 
glycosylation capillary zone electrophoresis is simple and less time consuming 
technique and can be conveniently used for screening large number of samples 4. 
Diagnosis of CDG should then be confirmed by the isoelectric focussing of serum 
transferrin, enzyme analysis and genetic studies. 
 
 Although at present there is no specific treatment that cures CDG, 
symptomatic treatment reduces the morbidity in these patients. Treatment of CDG 
requires a panel of specialists. The panel should include paediatrician, neurologist, 
ophthalmologist, surgeons, gastroenterologist, cardiologist, speech pathologist, 
laboratory professionals and other health care professionals who have to 
systematically plan and act for the affected patient’s treatment.  Three types of 
CDG have an existing therapy. Researchers are studying enzyme replacement 
therapy and gene therapy to cure this disorder.   
 
 Therefore screening the patients with symptoms of CDG and delineating 
them from other metabolic disorders is essential for future therapy.  
  
Review of Literature 
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REVIEW OF LITERATURE 
 
GLYCOBIOLOGY 
  “Glycobiology is defined as the study of the role of sugars in health and 
disease” 5. “The glycome is defined as the entire complement of sugars, whether 
free or present in more complex molecules, of an organism. 
 
 “Glycomics is the comprehensive study of glycomes, including genetic, 
physiologic, pathologic and other aspects” 5. 
 
 Certain oligosaccharide molecules contain specific biologic information, 
depending upon their constituent sugars, their linkages and their sequences. The 
biologic information is expressed via the interactions between specific sugars in 
glycoconjugates with the proteins or other molecules. Which lead to changes of 
cellular activity. Thus, the so called “sugar code of life” (one of the principal aims 
of glycomics) requires the description of the interactions that sugars and sugar 
containing molecules participate in, and the results of these interactions on 
cellular behavior 6. 
 
 Research in glycomics will provide the structural information on 
glycoconjugates, disclose “the sugar code of life”. It may also expose many 
significant sugar dependent biologic interactions that are vital for life. This can 
also endow with targets for drugs and other therapies. Since appropriate analytical 
technical are now available, the pace of research in glycomics is accelerating. 
 
 
  
 
Figure 1: O-linked glycans and N-linked glycans 
 
(Courtesy: untitled illustration of O-linked and N-linked glycans,Retrieved on september 
1,2016  from http://www.neb.com/applications/glycobiology) 
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GLYCOSYLATION 
 Glycosylation refers to the process of attaching the carbohydrate 
chains to proteins, lipids, or other organic molecules. Glycosylation is an enzyme 
mediated site-specific process, while glycation is not enzyme mediated. 
 
 “Glycation is a non enzymatic process of adding sugar moiety to a non 
carbohydrate molecule”1.  The enzymatic process of glycosylation produces 
glycoconjugates that is of vast clinical significance. “Glycoconjugate is defined as 
the molecule containing one or more carbohydrate chains covalently linked to 
protein or lipid”1.Glycoproteins are one class of glycoconjugates.Most of the 
proteins undergo glycosylation reaction after being synthesized in the rough 
endoplasmic reticulum. As S Hiroyuki Kajirightly states that“It has been 
estimated that approximately 50 % of eukaryotic proteins have sugars attached, so 
that glycosylation is the most frequent post translational modification of 
proteins”7. Almost all the plasma proteins of humans with the notable exception 
of albumin are glycoproteins. Glycoproteins are present in almost all organisms 
i.e. from viruses and bacteria to human beings,The carbohydrate content of 
glycoprotein ranges from 1% to over 85% by weight 8. 
 
Sugar donors involved in glycosylation: 
 In majority of the biosynthetic reactions only the nucleotide sugars are 
involved in glycosylation. Neither the free sugars nor the phosphorylated sugars 
are involved in glycosylation reactions. Uridine diphosphate glucose (UDP-Glc) 
was the first nucleotide sugar reported to be involved in glycosylation reactions 
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.Later other nucleotde sugars were found to be involved in glycosylation 
reactions. Some of the common nucleotide sugars involved in the synthesis of 
glycoproteins are UDP-Gal, UDP-Glc, GDP-Man CMP-NeuAc, GDP-Fuc, UDP-
GalNAc, UDP-GlcNAc UDP-Xyl. 
 
 It is not clear that why some nucleotide sugars contain UDP and others 
contain GDP/CMP.The bond or linkage formed between the sugar and the 
phosphate group in a nucleotide sugar is of high group transfer potential and high 
energy type. Nucleotide sugars are the active forms of sugars which can be then 
transferred in the presence of appropriate transferase enzymes to a suitable 
acceptor.  
 
Transport of sugar donors to the site of glycosylation: 
 Nucleoside triphosphates are the precursor molecules required for the 
generation of activated nucleotide sugars. This reaction takes place in the cytosol 
of cells except the CMP-sialic acids which are formed inside the nucleus.Since 
most of the glycosylation reactions takes place within the lumen of the golgi 
complex and/or endoplasmic reticulum,a carrier system is required to transport the 
activated nucleotide sugars from the cytosol to the lumen of the golgi apparatus 
across the golgi membrane .These carrier systems are mostly antiport systems 
i.e.,movement of one molecule of the activated nucleotide sugar is balanced by 
the transfer of another corresponding nucleotide.This carrier system/transport 
mechanism thus ensures sufficient concentration of each nucleotide sugar inside 
the lumen of the golgi apparatus.  
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 The sugar moieties are transported to the endoplasmic reticulum or Golgi 
apparatus for glycosylation by two mechanisms 
 
1) By dolichol phosphate transporter (dolichol is a polyisoprenoid, which is a 
metabolic intermediate in cholesterol synthesis) 
2) By specific nucleotide sugar transporters (NSTs). 
 
 UDP present in the lumen of the golgi complex is converted to UMP by the 
action of phosphatase enzyme . 
 UMP in the lumen of golgi complex  is exchanged for Both UDP-galactose 
(UDP-Gal) and UDP – N-acetylgalactosamine (UDP-GalNAc) into the cytosol. 
Therefore UDP-Gal and UDP-N-acetylgalactosamine is transferred inside the 
lumen of the golgi complex.  
 This transport mechanism takes place through the two different types of 
antiporters found in the golgi membrane.  
 This transport mechanism is mediate by two enzymes namely 
galactosyltransferase and N-acetylgalactosaminyltransferase .  
 A different transporter is found to transfer the inorganic phosphate (Pi) formed 
during the conversion of UDP to UMP to move out of the the Golgi cistern. 
 Other known antiporters permit CMP – N-acetylneuraminic acid to enter the 
lumen of Golgi complex in exchange for CMP. 
 
  
  
Figure 2: The transport mechanism for the uptake of nucleotide sugars into 
Golgi apparatus 
 
 
 
(Courtesy: untitled illustration of golgi complex transporters, Retrieved on September 
10,2016 from   http://www.cryst.bbk.ac.uk/pps97/assignments/projects/emilia/ 
Biosynthesis.HTM ) 
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Glycoconjugates –the end product of glycosylation: 
 “Glycoconjugates are carbohydrates that are covalently linked to other 
biological molecules (aglycone) such as amino acids, proteins, lipids and other 
small molecules”5. 
 
Classification of glycoconjugates: 
 The glycoconjugates are classified based upon the type of aglycone 
molecule attached and on the relative proportions of the carbohydrate/ aglycone 
parts. 
Thus glycoconjugates are classified as 6 
1. Glycoproteins 
2. Glycolipids 
3. Peptidoglycans 
4. Proteoglycans 
5. Lipoglycans 
 
Glycoproteins 7: 
 Oligosaccharide side chains are covalently attached to polypeptide side 
chains to form glycoproteins. This covalent attachment happens either as a 
cotranslational or posttranslational modification of a protein. 
 
 The principal oligosaccharide side chains found in glycoproteins are β-D-
Glucose, β-D-mannose, α-L-fucose, β-D-Galactose N acetyl galactosamine, N-
Acetyl glucosamine, N-Acetyl Neuraminic acid ,xylose. 
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Bonds involved in a glycoprotein: 
There are two types of bonds involved in a glycoprotein:  
 Glycosidic bonds between the carbohydrate residues in a glycan molecule. 
 The bond between the carbohydrate side chain and the protein molecule. 
 
In a glycan molecule the carbohydrate residues are linked by the glycosidic 
bonds formed between the carbon 1 and carbon 4 of the glycans. Since the 
glycosidic bond formation is an energy requiring mechanism, the energy is 
supplied by the hydrolysis of ATP to ADP 9.while, the addition of a glycan 
molecule to the protein necessitates the recognition of a consensus 
sequence.“Consensus sequence is defined as a sequence of DNA that has similar 
structure and function in different organisms” 9. 
 
Three classes of glycans/glycoproteins produced are: 
1. N-linked glycoproteins 
2. O-linked glycoproteins 
3. Glypiation products. 
 
N-linked glycans: 10 
 N-linked glycosylation, is the process of attaching the oligosaccharide to 
the asparagine aminoacid of the protein molecule through the amide linkage. N-
linked glycoproteins are the major class of glycoproteins that has been much 
studied. It includes both membrane bound and circulating glycoproteins. 
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The synthesis of N-linked glycoproteins involve 3 major steps .They are as 
follows: 10 
1. Dolichol-linked precursor oligosaccharide synthesis 
2.  Transfer of the precursor oligosaccharide to the protein molecule 
3. Processing of the protein linked oligosaccharide 
 
Site of N-linked glycosylation: 
1. First two steps i.e.dolichol-linked precursor oligosaccharide synthesis, transfer 
of the precursor oligosaccharide to the protein molecule and initial processing 
of the oligosaccharide linked protein molecule, takes place in the endoplasmic 
reticulum (ER).  
 
2. Consecutive processing and modification of the oligosaccharide linked protein 
molecule takes place in the Golgi complex. 
 
From the above it is clear that the synthesis of a glycoprotein requires different 
subcellular organelles i.e. endoplasmic reticulum and Golgi complex. Thus for 
N-linked glycoprotein to get synthesized, it requires an accessibility to 
different enzymes present within different subcellular organelles. Interestingly 
all N-linked glycoproteins are synthesized from a general core glycan 
structure. This takes place through a common pathway 10 .The core glycan 
structure consists of three mannose residues and two N-acetyl glucosamine. 
Following which further modifications of the general core glycan structure 
into variety of different glycoproteins takes place. 10   
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1.Dolichol-linked precursor oligosaccharide synthesis 
 The first process in the synthesis of dolichol linked precursor 
oligosaccharide is the formation of dolichol-linked GlcNAc sugar. Dolichol which 
is an intermediate in the cholesterol synthetic pathway is a lipid molecule made up 
of repeated isoprenoid units and is attached to the membrane of the ER. 
Pyrophosphate linkage is formed between the dolichol and the sugar molecules 
10.The oligosaccharide chain is then extended by adding together a variety of 
sugar molecules to the precursor oligosaccharide in a step-wise fashion. 
 
The formation of this precursor oligosaccharide takes place in two phases: 10. 
 Phase I –it occurs in the cytoplasmic side of ER  
 Phase II – it occurs in the luminal side of ER. 
 The resultant precursor molecule which has to be transferred to a protein 
comprises of 2 GlcNAc, 3 glucose and 9 mannose molecules. 
 
Phase I: 
 On the cytoplasmic side of the ER, two UDP-GlcNAc residues are attached 
to the dolichol molecule.A pyrophosphate linkage is formed between the 
dolichol and UDP-GlcNAc . 
 Glycosyltransferase catalyses the attachment of five GDP-Man residues to 
the GlcNAc disaccharide 
 Thus the resulting precursor molecule in phase one is Dolichol - GlcNAc2 - 
Man5 
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 Dolichol - GlcNAc2 - Man5 is then translocated across the membrane of 
endoplasmic reticulum to the lumen of the endoplasmic reticulum so that the 
precursor molecule is made accessible to the enzymes present in the lumen of the 
endoplasmic reticulum. Enzyme flippase is responsible for this translocation 
process. 
 
Phase 2: 
 In the endoplasmic reticulum, 4 mannose and 3 glucose molecules are 
attached to the Dolichol - GlcNAc2 - Man5 present on the luminal side. 
 Dol-P-Man & Dol-P-Glc are attached to the dolichol molecule formed in 
phase one which is then transported from the cytoplasm of the ER into the 
lumen of ER by the enzyme flippase. 
  Thus the resulting precursor molecule in phase two is Dolichol - 
GlcNAc2 – Man9-Glc3. 
 
  
 Figure 3: Synthesis of precursor oligosaccharide  
 
 
(Courtesy: untitled illustration of Precursor oligosaccharide synthesis, retrieved on 
august 4,2016.from http://www.studyblue.com/notes/note/n/lecture-5/deck/5362534) 
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Dolichol phosphate  is strongly hydrophobic and long enough to span 
a phospholipid bilayer membrane four or five times.  
 
The figure illustrates that: 
 Steps1 to 3: Two N-acetylglucosamine, one phosphate, and five mannose 
residues from UDP sugars are added one at a time to a dolichol phosphate on 
the cytosolic face of the ER membrane. 
 
 Step 4: Then the dolichol pyrophosphoryl oligosaccharide is flipped to the 
luminal face  
 
 Steps 5, 6: The remaining four mannose and all three glucose residues are 
added, yielding the completed Glc3Man9(GlcNAc)2 precursor, which is transferred 
to proteins.  
 
 In the latter reactions the mannose or glucose is first transferred from 
a nucleotide sugar to a carrier dolichol phosphate on the cytosolic face of the ER; 
the carrier is then flipped to the luminal face where the glucose or mannose is 
transferred to the growing oligosaccharide, and the carrier is flipped back again to 
the cytosolic face. Five residues in the final precursor are conserved in the 
structures of all N-linked oligosaccharides on secreted proteins 
 
2. Transfer of the precursor oligosaccharide to the protein molecule 
 After the formation of the precursor oligosaccharide Dolichol - GlcNAc2 – 
Man9-Glc3, it is conveyed to the nascent polypeptide. This process takes place in 
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the lumen of the ER. Energy required for this reaction is obtained from the 
cleavage of the pyrophosphate bond between the dolichol glycan molecules.  
Before a glycan is relocated to an emerging polypeptide it has to satisfy the 
following conditions:10 
1. The primary structure should have asparagine situated in a specific consensus 
sequence. 
2. Asparagine should have to be place precisely in the 3D structure of the 
protein.i.e. asparagine should be present on the surface of the protein 
molecule to which the sugar molecules need to be attached.Since sugar are 
polar molecules, it should not be buried in the interior of the protein. 
3. For the initiation of N-Linked glycosylation, Asparagine has to present in the 
luminal side of the endoplasmic reticulum.  
 
 The enzyme Oligosaccharyltransferase recognises the consensus sequence 
and transfer the glycan precursor to the polypeptide molecule in the lumen of the 
endoplasmic reticulum. N-linked glycosylation occurs cotranslationally.  
 
3. Processing of the protein linked oligosaccharide 
Processingof N-glycan takes place in the endoplasmic reticulum and in the golgi 
body. 
 1. Initial processing of the precursor molecule in endoplasmic reticulum 
 2. Subsequent processing in golgi body 
Initial processing of the precursor molecule in endoplasmic reticulum: 
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It is a quality control step that checks protein folding.If the protein is correctly 
folded,an enzyme known as glycosidases (glucosidase1 & 2)will remove three 
glucose moieties from the glycoprotein structure . Glycosidase cleave the 
glycosidic bonds by using a molecule of water.Once the third glucose moiety is 
removed from the glycoprotein structure, it moves from ER to the cis golgi . But 
if the protein is not properly folded (i.e. unfolded or partially folded), a chaperone 
protein will bind to the misfolded protein to assist in protein folding. The 
chaperone proteins are calnexin /calreticulin. 
 
 Once these reactions are completed, the newly synthesized protein is then 
transferred to the golgi for subsequent processing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4: Transfer of the precursor oligosaccharide to the protein molecule 
and initial processing of N-linked oligosaccharides (in the rough ER) 
 
 
(Courtesy: untitled illustration of precursor oligosaccharide transfer, Retrieved on august 
10, 2016 fom http//www.studyblue.com/notes/note/n/lecture-5/deck/5362534) 
 
 
 
 
  
  
 
Figure 5: Subsequent processing of precursor oligosaccharide in the golgi 
body: 
 
(Courtesy: untitled illustration of precursor oligosaccharide processing, retrieved on 
august 10,2016. from http://www2.nsysu.edu.tw/wzhlab/cell%20biology% 
20PDF/Ch%2014%20part%20I)  
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 In the cis Golgi three mannose residues are removed. The protein then 
moves from cis Golgi to the the medial-Golgi. Where, one GlcNAc residue is 
added and two more mannose residues are removed.folloeing which Two GlcNAc 
residues are added and One fucose molecule is attached. Then Three galactose 
molecules are added in the trans golgi and the processing is thus completed. 
Finally to each galactose residue N-acetylneuraminic acid is added. 
 
 Addition of sugar residues is catalyzed by glycosyltransferases and 
removal of sugar residues is by glycosidases. 
 
 Few mannose residues are detached by enzyme mannosidases in the cis 
golgi. 
 
 In the medial portion of golgi complex- some sugar residues are added by 
glycosyltransferases which results in the formation of mainly three types of 
glycoproteins. They are named as high mannose glycans, hybrid glycans and 
complex glycans depending upon their mannose content. 
 
 High mannose glycans- two N-acetylglucosamines with many mannose 
residues. 
 Hybrid glycans-one side of the branch consists of a mannose residues, whereas 
Nacetylglucosamine recruits a complex branch on the other side. 
 Complex glycans- it consists of greater than two N-acetylglucosamines along 
with any number of  other kinds of sugar moeities 
 
 
  
 
Figure 6: Type of N-glycans 
 
(Courtesy: untitled illustration of N-glycans,retrieved on september 4 ,2016. from 
http://www.dx.doi.org/10.3389/fped.2015.00054) 
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O-linked glycans: 
  “O-linked glycosylation is defined as the process which involves the 
attachment of a sugar molecule to the oxygen atom of an aminoacid in a protein” 
11. It occurs in the golgi apparatus .12 
 
 In other words O-linked glycosylation is the process of adding 
Nacetylgalactosamine to serine /threonine residues in a protein by the enzyme 
UDP-Nacetylgalactosamine: polypeptide Nacetylgalactosaminyltransferase. 
 
Glycoprotein in humans consists of four types of O-glycosidic linkages. 
1. GalNAcSer (Thr) bond is the predominant linkage.Usually a Galactose or 
Neuraminic acid residue is added to the GalNAc, However the composition 
of the sugars and length of the oligosaccharide varies in the glycoprotein. 
One example for this type of linkage is mucins. 
2. Gal-Gal-Xyl-Ser trisaccharide linkage is the second type of linkage.eg: 
proteoglycans consists of this type of linkage. 
3. Gal-Hydroxylysine (Hyl) linkage is the third type of linkage.eg: collagens 
contains such linkage. 
4. Many nuclear proteins and cytosolic proteins are made up of  side chains 
comprising of a single GlcNAc added to a serine / threonine 
residue.(GlcNAc-Ser[Thr]).This linkage comprises the fourth type . 
 
Sugars involved in O- linked glycosylation are: 
O-Nacetylgalactosamine (O-GalNAc), O-fucose, O-glucose,  
O-Nacetylglucosamine(O-GlcNAc),O-mannose 
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Examples of O-linked glycoproteins: 
1. Collagen  
2. Glycogenin. 
 
 In collagen lysine residues are hydroxylated to hydroxylysine to which a 
galactose residue is added by glycosylation. A molecule of glucose is then added 
and the structure is elongated . Glycosylation of hydroxylysine take place in the 
ER and Golgi apparatus 13.  
 
 This glycosylation is obligatory for appropriate functioning of the collagen. 
The only glycosylated tyrosine in nature is the glycogenin. Glycogenin is a 
glycosyl transferase enzyme required for the polymerization of glucose molecules 
into glycogen. 
 
Glipiation: 
 Many membrane associated proteins neither belong to the peripheral nor to 
transmembrane class. A glycosyl phosphotidyl inositol linkage (GPI) to the 
carboxy terminal of protein links the protein to the outer aspect of plasma 
membrane. This type of membrane attachment is referred to as GPI linkage. 
 
 The phosphotidyl iositol is linked to the glycan chain. In turn the 
oligosaccharide is attached through phosphoryl ethanolamine to the carboxy 
terminal of the amino acid.  
 
 
  
 
Figure 7: GPI anchor 
 
(Courtesy: untitled illustration of GPI anchor,Retrieved on september 4, from  
http://www.researchgate.net) 
It involves atleast 10 reaction coded by 20 different genes. 
 
 
 
 
 
 
 
 
19 
 
 
Examples of GPI linked proteins are : 
II. Acetylcholinesterse (red cell membrane) 
III. Thy-1-antigen (brain,T-Lymphocytes)  
IV. decay accelerating factor (red cell membranes) 
V.  alkaline phosphatase ( intestine,placenta) 
VI. 5’nucleotidase (T Lymphocytes) 
 
Hepatocyte mediated removal of certain glycoproteins from plasma 
 In 1970s Ashwell and his colleagues performed an experiment to 
understand the functional significance of oligosaccharide side chains in 
glycoproteins. 
 Rabbit's ceruloplasmin was treated with neuraminidase in vitro. 
 Normally the terminal neuraminic acid residues cover the subterminal 
galactose residues. By treatment with neuraminidase the galactose residue 
is exposed in the ceruloplasmin.  
 When the clearance of an untreated protein is compared with the 
neuraminidase treated protein,it was found that the neuraminidase treated 
ceruloplasmin disappears quickly from the circulation  
 However, if the neuraminidase treated protein was subjected to treatment 
with galactosidase, the clearance rate in the plasma was found to be 
normal. 
 Later studies showed that hepatocytes consists of mammalian 
asialoglycoprotein receptor which identifies the galactose of desialylated 
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glycoproteins .This process results in endocytosis of the desialylated 
glycoprotein.  
 This work indicated that Gal play an important role in governing the time 
of residence of certain glycoproteins in the circulation. 
 
Functions of the oligosaccharide chains of glycoproteins: 
1. It is involved in the modulation of  physicochemical properties of the 
glycoprotein for ,eg, 
 solubility 
 viscosity 
 charge 
 conformation 
 denaturation 
 binding sites for various bacteria, viruses and parasites. 
2. It protects the glycoproteins from proteolysis. 
3. It regulates the proteolytic processing of precursor proteins into to smaller 
residues 
4. It regulates the insertion of the glycoprotein into membranes, 
5. It affects the intracellular migration, sorting and secretion of glycoproteins 
6. It regulates embryonic development and differentiation 
7. It is involved in selecting the site of metastasis for the spread of cancer cells. 
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Functions served by glycoproteins include: 
1. Specific glycosylation pattern essential for the migration of immune cells: 
a) N-glycans on the immune cell directs them to migrate to the appropriate 
site.Intercellular adhesion of specific cells such as leukocytes and 
endothelial cells is due to the presence of specific glycoproteins on their 
surfaces called selectins. Selectins are calcium binding transmembrane 
proteins with a number of domains. They are single chain molecules whose 
aminoterminal ends comprises the lectin domain.The lectin domain has its 
specific carbohydrate residues. 
 
The intercellular adhesion of immune cells such as neutrophils to the endothelial 
cells of venules occurs in 3 stages: 
1. When the endothelium is injured or inflammation occurs at the site, the 
neutrophils will slowly roll within the vessel wall .This event is mediated 
by the selectins. 
2. Interaction between the activated CD18 integrin present on the neutrophils 
with the ICAM1 present on the endothelial cells leads to the adhesion of 
the activated neutrophils to the endothelium.. 
3. Later with the help of PECAM1 the neutrophils will migrate through the 
junction of the endothelial cells into the interstitium. 
 
b) The glycosylation pattern on the immunoglobulins alter their affinities to 
immune receptors. 
  
 
Figure 8: Intercellular Adhesion Of Immune Cells 
 
(Courtesy: untitled illustration of immune cells migration, Retrieved on September 
5,2016. From https://www.studyblue.com/notes/note/n/case-2/deck/2532289) 
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c) The major histocompatibility complex (MHC) are glycoproteins present on 
the surface of cells and interact with T cells producing an adaptive immune 
response. 
d) Leukocytes contains sialyl Lewis X antigen (glycoproteins) which plays an 
important role in cell-cell recognition on their surface. 
e) Blood group antigen such as H antigen is a glycoprotein. 
f) Factors IIb/IIIa responsible for platelet aggregation and adherence to the 
surface of endothelial cells is the glycoprotein. 
 
2. Affects folding of certain proteins through calnexin/ calreticulin cycle. 
 
3. Involved in the fertilization of oocyte: 
 Zona Pellucida (ZP) is a thick, noncellular, transparent layer that surrounds 
the oocyte. 
 To enter the oocyte, the sperm has to traverse this layer.  
 The zona pellucida cosists of three glycoproteins namely, ZP-1, ZP-2, ZP-3, 
of which ZP3, which is an O linked glycoprotein is responsible for the 
attachment of sperms.  
 Galactosyltransferase is a protein present on the surface of the sperm, which 
interacts with the carbohydrate chains of ZP3 inducing an acrosomal 
reaction. The acrosome of the sperm contains enzymes such as proteases and 
hyaluronidases which gets released. Release of these enzymes will help the 
sperm to traverse the zona pellucida and enter the plasma membrane of the 
oocyte.  
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 Fertilization can be inhibited by development of drugs and antibodies that 
hinder the functions of ZP3.This would thus act as contraceptive agent. 
 
4. Role of glycoprotein in polyspermy block: The GPI protein 
IZUMO1R/JUNO (named after the Roman goddess of fertility) released from 
the plasma membrane of egg does not allow the sperm to fuse with the egg. 
This mechanism contributes to the polyspermy block at the plasma 
membrane in eggs. 
5. Both N-linked and O-linked glycoproteins are present as structural 
components in the cell wall and extracellular matrix and help to connect 
together the cells and ground substance of the connective tissue. Mediates 
Cell to Cell and Cell Matrix interactions. 
6. O linked glycoproteins form component of mucosal secretions which gives 
the mucus its slimy feel. 
7. Mannose-6-phosphate is a chemical marker which targets the lysosomal 
enzymes to the organelle. 
8. Glycoproteins play a significant roles in the human physiology as 
 Hormones-   FSH, LH, TSH, HCG, Erythropoietin (EPO).  
 Alpha-fetoprotein 
 Transport molecules-  Transferrin  ,Ceruloplasmin 
 Enzymes- Alkaline phosphatase 
 Receptors- various proteins involved in hormone and drug action. 
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Factors that regulate the glycosylation of glycoprotein: 
 Glycosylation is a complex process which involve large number of 
enzymes. Glycosylation involves approximately 1 % of the human genome .It 
involves about ten distinct GlcNAc transferases and multiple species of  other 
glycosyl transferases. 
Factors that affect oligosaccharide assembly and transfer are: 
1) Availability of appropriate acceptors on the proteins. 
2) Presence of tissue  Dolichol phosphate. 
3) Oligosaccharide: protein transferase activity. 
4) Appropriate conditions for enzyme activity which includes : 
a) The type of the cell and the processing enzymes they contain.  
b) The type of species - since same cells obtained from different 
species show different types of processing enzymes. 
c) Intracellular location of the enzymes. 
d) Conformation of the protein. 
 
Methods used to analyze glycoproteins: 
 Various methods available to analyze glycoproteins are: Isoelectric 
focusing, Capillary zone electrophoresis, High performance liquid 
chromatography, Treatment with suitable endo/exoglycosidase or phospholipases, 
Agarose-lectin column chromatography14-20, Mass spectrometry21, NMR 
spectroscopy22, Multi-angle light scattering, Dual Polarisation Interferometry, 
Methylation (linkage) analysis, Periodic acid-Schiff stain,  Amino acid or cDNA 
sequencing. 
25 
 
 
CONGENITAL DISORDERS OF GLYCOSYLATION 
  “Congenital disorders of glycosylation (also known as carbohydrate-
deficient glycoprotein syndrome) is an inborn error of metabolism in 
which glycosylation of a variety of tissue proteins and/or lipids are deficient or 
defective”23. 
 
 In other words “Congenital disorders of glycosylation (CDG) is an 
umbrella term for a rapidly  expanding group of rare genetic, metabolic disorders 
due to defects in complex chemical process known as glycosylation”23  and is also 
known as CDG syndrome. 
 
 CDG is an autosomal recessive condition24 that presents with a broad 
clinical presentation affecting multiple organ system. The range of severity is 
wide. It can be a mild disorder with asymtomatic patients or it can be even fatal 
leading to death. 
 
 Moderate and severe CDGs usually present at infancy itself.  
 
 Even though it is a multisystem disorder, in most of the CDGs neurological 
symptoms predominate25. 
 
 Till now approximately about 100 different types of CDG have been 
identified. 
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Classification of CDG23,26: 
(CDG) are classified into three groups:   
Group I:  defect in the formation of lipid linked oligosaccharide and its transfer to 
a nascent glycoprotein. 
Group II: defect in the processing of the nascent glycoprotein. 
Group X: defects not yet completely characterized 
 
Congenital disorder of N-linked glycosylation classification (as of June 2001):  
Group 
Defect and 
localization(cytoplasm,endoplasmic 
reticulum,golgi apparatus) 
Defective 
gene Synonym 
I  
Defect in the assembly of 
dolicholpyrophosphate  linked 
oligosaccharide chain 
 CDG-I 
PMM(C) PM2 CDG-Ia 
MPI(C) MPI CDG-Ib 
ALG6(ER) ALG6 CDG-Ic 
ALG3(ER) DPM1 CDG-Id 
Dolichol-P-mannose synthase I(ER) DPM1 CDG-Ie 
II 
Defect in the processing of protein 
bound oligosaccharide chain  CDG-II 
N-acetylglucosaminyltransferase 
II(GA) MGAT2 CDG-IIa 
Glucosidase I(ER) GLS1 CDG-IIb 
GDP-fucose transporter(GA) FUCT1 CDG-IIc 
X Defects not yet completely characterised 
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The drawbacks of older classification is that  
  It is based on the order of discovery of the types of CDG disorder, 
 It is a very complex classification which adds no clinical value.  
Therefore this has led to the proposal of new classification by J. Jaeken in August 
2008. 
New  nomenclature for CDG:27 
1) Defects in protein N-glycosylation  
2) Defects in protein O-glycosylation  
3) Defects in glycosphingolipid and glycosylphosphatidylinositol anchor 
glycosylation  
4) Defects in multiple glycosylation and other pathways 
 
1. Defects in protein N-glycosylation: 
CDG subtype Gene mutation Enzyme defect 
CDG-Ia PMM2 Phosphomannomutase 2 
CDG-Ib MPI Phosphomannose isomerase 
CDG-Ic ALG6 glucosyltransferase 1 
CDG-Id NOT56L mannosyltransferase 6 
CDG-Ig ALG 12 mannosyltransferase 8 
CDG-Ih ALG 8 glucosyltransferase 2 
CDG-Ii ALG2 mannosyltransferase 2 
CDG-Ij DPAGT1 UDP-GlcNAc:Dol-P-GlcNAc-P transferase 
CDG-Ik HMT1 mannosyltransferase 1 
CDG-Il DIBD1 mannosyltransferase 7-9 
CDG-In RFT1 Flippase of Man5GlcNAc2-PP-Dol 
CDG-Iia MGAT2 N-acetylglucosaminyltransferase 2 
CDG-Iib GLS1 Glucosidase 1 
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2. Defects in protein O-glycosylation:  
O-xylosylglycan synthesis 
(multiple cartilaginous 
exotoses) 
 
EXT1/EXT2 
B4GALT7 
Glucuronyltransferase/N-
acetylglucosaminyltransferase 
b-1,4-galactosyltransferase 7 
O-N-
acetylgalactosaminylglycan 
synthesis 
(familial tumoral 
calcinosis) 
GALNT3 
Polypeptide N-
acetylgalactosaminyltransferase 
3 
O-xylosyl/N-
acetylgalactosaminylglycan 
synthesis 
(Schneckenbecken 
dysplasia) 
 
SLC35D1 Solute carrier family 35 member D1 
O-mannosylglycan 
synthesis 
cong. muscular dystrophy 
 
 
POMT1/POMT2 
 
 
POMGNT1 
 
FKTN 
FKRP 
LARGE 
Protein-O-mannosyltransferase 
1/proteinO-mannosyltransferase 
2 
Protein-O-mannose b-1,2-N-
acetylglucosaminyltransferase 
Fukutin 
Fukutin-related protein 
N-
Acetylglucosaminyltransferase-
like protein 
O-fucosylglycan synthesis 
(spondylocostal dysostosis 
type 3) 
(Peters plus syndrome) 
SCDO3 
 
 
B3GALTL 
O-Fucose-specific b-1,3-N-
acetylglucosaminyltransferase 
 
O-Fucose-specific b-1,3-
glucosyltransferase 
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3. Defects in glycosphingolipid and glycosylphosphatidylinositol anchor 
glycosylation: 
Amish infantile epilepsy SIAT9 GM3 synthase 
glycosylphosphatidylinositol 
deficiency PIGM 
Phosphatidylinositolglycan, 
class M 
 
4. Defects in multiple glycosylation and other pathways: 
CDG-Ie DPM1 Dol-P-Man synthase 1 
CDG-If MPDU1 Man-P-Dol utilization 1 
CDG-Iid B4GALT1 b-1,4-galactosyltransferase 1 
hereditary inclusion 
body myopathy GNE 
UDP-GlcNAc 
epimerase/kinase 
CDG-Iif SLC35A1 CMP-sialic acid transporter 
CDG-Iic SLC35C1 GDP-fucose transporter 
CDG-Im DK1 Dolichol kinase 
CDG-Iie COG7 Golgi complex 7 
CDG-Iig COG1 Golgi complex 1 
COG8 
Golgi complex 8 
cutis laxa type II V-ATPase ATP6VOA2 
V0 subunit A2 of vesicular 
H(+)-ATPase 
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Pathophysiology of CDG (N-glycosylation pathway) 
 In congenital disorder of glycosylation, defect in glycosylation is due to 
mutatant gene which encodes for enzymes involved in glysosylation. Deficient or 
defective glycosylating enzymes leads to the production of defective 
glycoproteins which causes wide range of symptoms involving multiple organ 
systems. 
The figure illustrates the N-Linked glycosylation pathway defects in CDG. 
 N-glycosylation pathway take place in the cytoplasm and endoplasmic 
reticulum. 
 In the cytoplasm glucose is converted into mannose which is then 
subsequently converted to GDP mannose. 
 GDP mannose is converted into dolichol phosphate mannose (reaction 5) and 
UDP glucose is converted into dolichol phosphate glucose( reaction 15). 
 Both the dolichol phosphate sugars are then flipped from cytoplasm to 
endoplasmic reticulum by the enzyme flippase.  
 Key enzymes in this pathway are: (1) phosphoglucose isomerase; (2) MPI; (3) 
PMM; and (4) GDP-Man synthase 28.  
 one molecule of GlcNAc-1-phosphate is transferred from UDP-GlcNAc to 
dolichol phosphate to form dolichol pyrophosphate GlcNAc, 
 To dolichol pyrophosphate GlcNAc, one molecule of GlcNAc is added to form 
dolichol pyrophosphate (GlcNAc)2 (reaction 6).  
 To dolichol pyrophosphate (GlcNAc)2 Five Man residues are  added  to form 
dolicholpyrophosphate(GlcNAc)2(Man)5 (reaction 7),  
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 To dolicholpyrophosphate (GlcNAc)2 (Man)5 four mannose residues and three 
glucose residues(reactions 10, 11, and 12) are added to form 
dolicholpyrophosphate Glc3Man9GlcNAc2 .  These mannose residues and 
glucose residues are obtained from dolichol phosphate mannose (reaction 9) 
and dolichol phosphate glucose.  
 From dolicholpyrophosphate Glc3Man9GlcNAc2, The Glc3Man9GlcNAc2 
oligosaccharide is transferred to the asparagine residue of the nascent 
glycoprotein  by the enzyme oligosaccharyltransferase (reaction 13)   
 The three Glc residues are then removed from the nascent glycoprotein by 
glycosidases. 
 Following which protein proceeds to the Golgi apparatus for further 
processing.  
 Defective enzymes at steps 3, 2, 10, 9, and 5 causes CDG types Ia, Ib, Ic, Id, 
and Ie respectively. 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
Figure 9: Outline of the N-glycosylation pathway and the enzyme defects in 
CDG subtypes: 
 
 
(Courtesy: Untitled illustration of N-linked glycosylation pathway defects,Retrieved on 
september 6, from http://www.nature.com/pr/journal/v52/n5/fig_tab/pr2002233f1.html) 
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Clinical features of CDG 28 
CDG-Ia (PMM deficiency): 
 CDG-Ia is the most common type of CDG with approximately about 300 
patients all over the world. It mostly presents during the neonatal 
/childhood period. 
 The typical clinical features of CDG include inverted nipples, fat pads, 
muscular hypotonia, strabismus, failure to thrive and elevated 
transaminases.  
 The most common clinical feature is cerebellar hypoplasia 
 “As a rule there is osteopenia” 29,30 
 It is due to mutation of PMM2 located on chromosome 16p13 31,32 .  
 Mortality of this subtype is about 25%, which occurs mostly during the 
early childhood due to infections or organ failures 33,34.  
 As the child grows, neurlogical symtoms such as mental retardation, 
retinitis pigmentosa ,seizures, strokelike episodes & cerebellar dysfunction 
become more obvious 
 In adults, nonprogressive ataxia, mental retardation, and peripheral 
neuropathy are more common. Therefore most of them are wheelchair 
bound. 
 Hypergonadotropic hypogonadism is the frequent symptom in adult 
female pateints.35,36. 
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Clinical stages of CDG-Ia37:  
Stage1-Infantile alarming multisystem involvement: 
Failure to thrive 
Floppiness 
Psychomotor retardation 
Abnormal subcutaneous fat pads 
Inverted nipples 
Hepatomegaly & liver dysfunction 
Cerebellar atrophy 
Esotropia 
Pericardial effusion 
Multisystem failure 
Stage 2-Childhood ataxia mental retardation: 
Mental retardation IQ 40-60 
Motor disability 
Peripheral neuropathy 
Cerebellar ataxia 
Retinal degeneration 
Stroke like episodes 
Seizures 
Stage 3-Teenage leg atrophy: 
Atrophy of lower limbs 
Stable crebellar ataxia 
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Deformity of thorax and spine 
Osteopenia 
Absence of puberty in females (hypergonadotrophic hypogonadism) 
Stage 4-Adult stable disability: 
Stable neurological impairment 
Short stature 
Kyphoscoliosis and long thin extremities 
Premature aging 
Retinitis pigmentosa 
 
CDG-Ib (MPI deficiency): 
 This disorder is due to MPI deficiency.  
 Approximately about 20 CDG-Ib patients are present worldwide. 
  The most comon clinical presentation include Proteinlosing enteropathy, 
congenital hepatic fibrosis, coagulopathy, vomiting and hypoglycemia. 
 This type of CDG present without overt neurologic manifestations 38-42.  
 It is one of the treatable CDG subtype with known therapy i.e. oral 
mannose therapy.  
  Early diagnosis is indispensable. 
CDG-Ic (ALG 6 deficiency): 
 This disorder is due to ALG 6 deficiency, this enzyme catalyzes the 
attachment of the first glucose to Man 9GlcNAc2PPdolichol in the ER.  
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 CDGIc causes mainly a neurologic disorder similar toCDG-Ia but features 
such as cerebellar hypoplasia, fat pads, polyneuropathy, and inverted 
nipples are missing 43,44. 
  The symptoms of CDGIc are general milder than CDG-Ia 45,46.  
 Since the typical morphological features and radiological findings such as 
cerebellar hypoplasia are absent, this type is mostly underdiagnosed. 
 In a very few patients the disease lead to a fatal outcome. 
CDG-Id (ALG 3 deficiency): 
 The defect is due to ALG 3 which transfers mannose from dolichol -
phosphate mannose to the lipid linked oligosaccharide intermediate 
Man5GlcNAc2PPdolichol. 
 In 1995, a child presented with microcephaly, severe epilepsy, global 
developmental delay and psychomotor retardation. It was first reported as 
CDG “type IV” 47.  
 The isoelectric focusing of serum transferrin showed no increase of 
asialotransferrin.  
 Till now only one patient is identified as ALG3 deficiency 48. 
 
CDG-Ie (dolichol-P-mannose synthase 1 deficiency): 
 CDG-Ie is caused by DPM1 gene mutation which leads to dolichol-P--
mannose synthase deficiency (EC 2.4.1.83) 49,50 
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 Four patients are reported with clinical features such as microcephaly, 
minimal psychomotor development, absent visual contact and severe 
epilepsy. 
 In two of the above said 4 pateints MRI brain revealed delayed myelination  
 Serum transferrin electrophoresis by isoelectric focusing showed only little 
or no increase of asialotransferrin.  
CDG -If: 
 It is due to mutations involving Lec35/MPDU1 gene leading to deficiency 
or defective dolichylphosphomannose and dolichyl phosphoglucose. Clinical 
features of this disorder include severe encephalopathy, dry scaling skin with 
erythroderma. 
CDG-IIa (Nacetylglucosaminyltransferase II deficiency): 
 CDG-IIa is due to mutations in MGAT2 gene which codes for the enzyme 
N-acetylglucosaminyltransferase II 51. 
 In the early 1990s two children were reported with cerebellar hypoplasia 
and severe psychomotor retardation.  
 But these patients did not have peripheral neuropathy. 
 Till now, four children have been identified as CDG-IIa 52,53.  
 Clinical features of this type include psychomotor retardation, craniofacial 
dysmorphy and stereotypic hands movement.  
 Glycan structural studies revealed a glycan pattern similar to congenital 
dyserythropoietic anemia type II 54,55.  
 N-acetylglucosaminyltransferase II deficiency was demonstrated in 
monocytes and fibroblasts 56,57.  
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CDG-IIb (glucosidase I deficiency): 
 This type of CDG is due to glucosidase enzyme deficiency. 
 Signs and symptoms of CDG-IIb include typical dysmorphic features such 
as retrognathia, high arched palate, and overlapping of fingers. 
  Other clinical features of this subtype include severe developmental delay, 
seizures, muscular hypotonia and recurrent edema. 
 Though serum transferrin electrophoresis by isoelectric focusing was 
normal, Isoelectric focusing of serum hexosaminidase revealed the 
abnormality.  
 The diagnosis of this disorder was by oligosaccharide analysis of urine 
which showed the presence of a Glc (α1–2) Glc (α1– 3) Glc (α1–3) Man 58.  
CDG-IIc (GDP-fucose transporter deficiency): 
 This disorder is due to GDP-fucose transporter gene mutation 
 This disorder is also  called as  leukocyte adhesion deficiency type II 59,60 
 Till now three patients have been reported 61,62 
 Clinical features include, severe psychomotor retardation, growth 
retardation, hypotonia, and craniofacial dysmorphism. 
 Neutrophils of these patients do not have Sialyl lewis x which is a 
carbohydrate containing molecule and responsible for cell adhesion. Sialyl 
Lewis x is required for the recruitment of neutrophils to the site of 
infection. Therefore the patients present with recurrent infections and 
marked leukocytosis. 
 Other fucose containing carbohydrate structures, such as A, B, O, and 
Lewis A blood groups, are also absent.  
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CDG-IId: 
 Due to deficient UDP-Gal: N-acetyl-glucosamine -1,4-
galactosyltransferase I enzyme  
 Clinical features include psychomotor retardation, macrocephaly and 
myopathy. 
CDG-x: 
 The number of CDG patients that cannot be included in the above 
mentioned subtypes is progressively increasing.  
 They may be due to different defects in the various other steps of the N 
glycosylation and O glycosylation pathways.  
 They present with wide range of clinical presentation such as : absent 
psychomotor development, progressive microcephaly, oligohydramnion, 
hypotonia,failure to thrive, hydrops fetalis, dysmorphy, early death after 
intractable seizures, 63 
Severe hypotonia, cataracts, death in status epilepticus 64, oligohydramnios, 
dysmorphy, hypotonia, diarrhea, vomiting, ascites,  seizures, cerebellar 
hypoplasia, severe thrombocytopenia 64, muscular hypotonia, infantile 
spasms 65 .demineralization of distal bones, tubulopathia 66, dysmorphy, 
 
 
 
 
 
 
Figure 10: Algorithm for the diagnosis of CDG30 
 
 
 
(Courtesy: Congenital Disorders of Glycosylation: A Review Stephanie Grünewald, 
Gert Matthijs and Jaak Jaeken) 
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DIAGNOSIS OF CDG: 
 Serum transferrin electrophoresis using isoelectric focusing is the gold 
standard technique in the diagnosis of congenital disorder of glycosylation.  
 
Human Serum Transferrin 
 Transferrin belongs to the class of single chain iron binding glycoprotein. 6 
% of the glycoprotein contains carbohydrate. It is a β 1 globulin whose 
molecular mass is about 80 KDA with 678 amino acids 67. Interestingly, 
the carbohydrate moiety of transferrin is not essential for its optimum 
function 68.   
 Apotransferrin gene is found at q21 on chromosome 3 near the gene for 
Transferrin receptor .Apotransferrin is produced in the liver.It has a half 
life of 8 days 67. It contains 2 homologous domains, one in both N and C 
terminal. Each of those domain contains one high affinity fe 3+ binding 
site67. 
  Iron binds apotransferrin through two tyrosine molecules, an aspartic acid 
residue and a histidine residue. An anion (bicarbonate or carbonate) is 
bound with each ferrin ion as a bridging ligand between protein and the 
iron 67. Affinity of apotransferrin to iron is a pH dependent process. In 
plasma with pH 7.4 apotransferrin very strongly binds the iron. But at pH 
less than 4.5 no binding occurs. This pH dependent affinity of transferrin 
play a significant role in the mechanism of iron release from transferrin 
under physiological conditions. 
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 Conformational changes in the protein leads to release & binding of iron by 
transferrin. In case of absence of iron, the two domains of transferrin are 
widely separated and it assumes an open configuration. However when 
iron binds to the transferrin the domains come close to the metal to assume 
a closed configuration state.  
 
The reference range of serum transferrin: 200 to 400 mg/dl  
Conditions causing increased transferrin levels:Iron depletion, Pregnancy, Oral 
contraceptives 
 
Conditions causing decreased transferrin levels:Ironoverload, Inflammation, 
Infection, Malignancy, Liverdisease, Nephritic syndrome and Malnutrition. 
  
 Figure 11 : Structure of transferrin 
 
 
 
(Courtesy: untitled illustration of transferrin structure, Retrieved on August 
10,2016 from http://www.medicine.org.hk/hkscc/communication/v5n1/p23-
26f.htm) 
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Microheterogeneity of human serum transferrin: 
Transferrin is synthesized by the  hepatocytes and  is made up of three domains  
i. A single polypeptide chain 
ii. Two metal ion binding sites  
iii. Two N linked complex glycan chains. 
 
 Transferrin shows distinct microheterogeneity. Even under nonpathological 
condition the transferrin substructures show distinct variability. 
 
 Human serum transferrin appears in the β region of serum protein 
electrophoresis on agarose gel. A multitude of transferrin bands appears in 
isoelectric focusing with immunoblot and staining. 
 
Effect of varying iron load: 
Each Transferrin molecule can bind with two metal iron, preferably Fe3+. 
Depending upon the availability of Fe3+, Transferrin molecules can be Iron 
free, Loaded with one Fe3+ ion (Fe1-Transferrin; Fe1N or Fe1C transferrin), 
Loaded with two  Fe3+ ions(Fe2-transferrin). In healthy individuals, transferrin 
iron saturation is 30%. In Fe3+ deficient state, iron saturation of transferrin 
decreases and increased levels of Fe0 and Fe1-transferrin is found in the serum.  
In Fe3+ excess state (hemochromatosis), iron saturation of transferrin increases 
and only Fe3+ isoform is found in the serum. 
The isoelectric point of the transferrin molecule decreases by 0.2 pH units for 
every Fe3+ ion binding. 
 
 Figure 12:  Transferrin isoforms 
 
 
 
(Courtesy: untitled illustration of transferrin isoforms ,retrieved on september 9,2016 
from http://www.ufrgs.br/imunovet/molecular_immunology/chemicalcauses_ 
ethanol.html) 
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Differing N-glycan chains 
 The two N-glycan chains in the transferrin molecule differs in their degree 
of branching with bi, tri and tetra antennary structures. Each antenna of the 
transferrin N-glycan chain terminates with a negatively charged sialic acid 
residue.Because of this, sialoisoforms of transferrin (i.e.asialotransferrin, 
monosialo,disialo,trisialo,tetrasialo,pentasialo,hexasialo, heptasialo,octasialo 
transferrin ) occurs in the serum. The relative amount of this transferrin isoforms 
as a percentage of total serum transferrin is : 
 
Transferrin sialo isoform Relative percentage 
Heptasialotransferrin <1.5% 
Hexasialotransferrin 1-3 % 
Pentasialotransferrin 12-18% 
Tetrasialotransferrin 64-80% 
Trisialotransferrin 4.5-9% 
Disialotransferrin <2.5% 
Monosialotransferrin <0.9% 
Asialotransferrin <0.5% 
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The octasialotransferrin is not in detectable amount in the serum under 
physiological condition. The isoelectric point of transferrin decreases by 0.1 pH 
unit for each sialic acid residue bound to the N-glycan chain. Genetic variants of 
transferrin is possible due to substitutions of aminoacid in the polypeptide chain  
Till now about 38 transferrin variants are known. 
 
The factors affecting isoelectric point of the transferrin molecule are: 
1. Ironload 
2. Amount of sialic acid  
3. Polypeptide chain polymorphisms  
 
 The alterations in isoelectric point is possible. When one or two Fe3+ ions 
are bound or lost, it can be compensated either by the presence or absence of sialic 
acid residues or by genetic variants of transferrin. Thus, transferrin molecules 
with differing iron content and sialic acid residues can have the same isoelectric 
point.for eg, disialo Fe2-Transferrin which is the main CDT isoform and terasialo 
Fe1-Transferrin which is the main non CDT isoform can have the same isoelectric 
points. 
 
  
44 
 
Isoelectric focusing (IEF): 
 IEF separates amphoteric compounds such as proteins with increased 
resolution in a medium possessing a stable pH gradient. The protein becomes 
focused at appoint on the gel as it migrates to a zone where pH of the gel matches 
the protein’s isoelectricpoint. At this point, the charge of the protein becomes zero 
and its migration ceases. The protein zones are very sharp, because the region 
associated with a given pH is very narrow. Proteins that differ in their pI values by 
only 0.02 pH units have been separated by isoelectric focusing. 
 
 In Isoelectric focussing mixtures of 50 to 100 different ampholytes with 
molecular weights of 300 to 1000 and different pKa values are added to the 
medium to create a natural pH gradient through which the proteins migrate and 
stop at their individual isoelectric points. 
 
 PAGE-IEF: It is widely used as it is free of electroendosmosis. The pore 
size of the polyacrylamide gel must be large enough so that protein migration is 
not impeded by molecular sieving effects. In actual practice, impeded migration 
of some proteins, such as IgM, cannot be prevented. With the availability of 
endosmosis free material, IEF methods have been adopted for agarose, cellulose 
acetate, and sephadex electrophoresis.  
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Isoelectric focusing of serum Transferrin: 
Transferrin, a serum glycoprotein has two N-glycosylation 
sites.Tetrasialotransferrin being the common sialoisoform in the serum .It 
consists of two biantennary chains with sialic acid residues in their terminal 
end. When synthesis of N-glycan is deficient, the incorporation of sialic acid 
residue which is a negatively charged residue becomes deficient.This leads to 
the acquisition of a more positive charge in the molecule. This leads to a   
cathodal shift in the isoelectric focusing of transferrin.Two types of abnormal 
patterns are commonly found in isoelectric focusing of serum transferrin. In 
type 1 pattern/pattern A (the most frequent pattern), there is a decrease in 
tetrasialotransferrin and increase in di and asialotransferrin. In type 2 pattern/ 
pattern B there is a combination of type 1 pattern along with increase in 
trisialo/monosialotransferrin.It is ideal to exclude that the abnormal pattern is 
not due to transferrin protein variant by performing Mass spectrometry of the 
patient’s serum transferrin or atleast by preincubating the sample with 
neuraminidase.IEF of other glycoproteins such as hexosaminidase, Thyroxine 
binding globulin and α-1 antitripsin, apo C-III helps to document the presence 
of generalized glycosylation defect in the pateint. The disadvantage of IEF is 
that defects in fucose cannot be diagnosed using IEF since isoelectric focusing 
is based upon sialic acid deficiency. This could be overcome by identifying 
the presence of Bombay blood group in the patient who is suspected to have a 
fucose defect. IEF was normal in one patient with CDGIIb 54.IEF of serum 
transferrin can also be normal in pateints with CDGIa 69. 
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Capillary zone electrophoresis of serum Transferrin an alternative to 
isoelectric focussing70: 
 
Capillary zone electrophoresis 
 In Capillary zone electrophoresis (CZE), the classic techniques of zone 
electrophoresis, isotachophoresis, isoelectric focusing and gel electrophoresis can 
be carried out in a small bore fused silica capillary tube of 10-100 μm internal 
diameter and 20 to200 cm in length. 
 
Two distinct advantages of capillary format are Higher voltage can be applied 
thereby migration of proteins can be made fast and Possibility of automation 
 
 CZE can be used to separate low molecular weight ions and uncharged 
molecules using the micellar electrokinetic chromatography (MEKC) mode.CZE 
can also be used for separation of inorganic ions, amino acids,organic   acids, 
drugs, vitamins, porphyrins, carbohydrates, oligonucleotides, proteins and DNA 
fragments. 
 
 In an electrophoretic apparatus, the capillary tube is connected to buffer 
reservoirs to which a high voltage power is supplied. This helps to obtain 
enhanced resolution and decreases the separation time. The capillary tube is 
connected to a detector at its end.The technique requires only few microlitres of 
sample. This minimizes distortions caused by the presence of excess of samples in 
the applied field. In contrast to the conventional electrophoresis, CZE is well 
47 
 
suited to automation. Samples are easily applied to the capillary, a variety of 
detector types can be used.  
 
The capillary tubes: 
 The capillary tubes used in CZE are made from fused silica covered with a 
thin polyimide coating which provides the tube strength and flexibility.. At the 
terminal end of the tube a small portion of the polyimide coating is removed, 
creating a window for online optical detection. The length of the capillary tubing 
is from 20 cm upto several metres with the outer diameter being 180 to 375 μm 
and inner diameter being 20 to 180μm. Rectanglar capillaries are more suitable for 
optical detection than their cylindrical counterparts as they provide a flat surface. 
The main advantage of performing electrophoresis in a narrow bore capillary is 
efficient heat dissipation. The large surface to volume ratio inherent in capillaries, 
however allows for more effective heat dissipation and much higher voltages can 
be applied, often upto 30 kV.An additional advantage gained from using a narrow 
bore capillary chamber is that it improves resolution by minimizing band 
broadening. 
 
Sample injection: 
 In CZE, sample volumes of less than few microlitres (1 to 50 nL) are 
loaded into the capillary chamber by one of two primary methods. Which are 
Hydrodynamic injection and Electrokinetic injection. 
 
 With hydrodynamic injection, the sample is applied by a positive pressure 
at the inlet or negative pressure at the outlet.. 
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 In electrokinetic injection, the sample is applied by a voltage for a timed 
interval. The magnitude of voltage used for sample application is usually 3 to 5 
times lower than the voltage used for separation. 
Direct detection: 
 With CZE, the analytes are separated fast. Detection is by an optical 
detector without prior staining. Optical detection is based on classical methods, 
such as photometric absorbance, refractive index, and fluorescence.  
 
Optical detection: 
 As with HPLC, ultraviolet visible photometers are widely used as 
detectors, the inner diameter of the capillary tube defines the optical light path 
(OLP) length of the tube. 
 
 This Capillary zone electrophoresis system can be used to screen patients 
suspected with congenital disorder of glycosylation by estimating and interpreting 
the carbohydrate deficient transferrin pattern. 
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Carbohydrate Deficient Transferrin 
 Transferrin isoforms, such as asialo Fe2-Transferrin, monosialo Fe2-
Transferrin, disialo Fe2-Transferrin were collectively known as carbohydrate 
deficient transferrin. The normal range for carbohydrate deficient transferrin is 
<1.3 % 
Trisialo Fe2-Transferrin and CDT: 
 Trisialo Fe2-Transferrin has no obvious diagnostic value and it should not 
be considered in CDT. This is because the concentration of Trisialo transferrin 
was exactly same in a pathological sample when compared to a non pathological 
serum samples having normal CDT concentration 71. 
 
Structure of human serum CDT: 
 The main CDT isoforms are disialo Fe2-transferrin and asialo Fe2-
Transferrin. They lack one or two complete glycan chains. The disialo Fe2-
transferrin has a single biantennary Nglycan chain with two sialic acid residues, 
where as asialo Fe2-transferrin consists of no carbohydrate structure therefore no 
sialic acid residues. 
 
 Trisialo Fe2-transferrin has two biantennary N-glycans, one with two 
terminal sialic acid molecules, the other with one terminal sialic acid and one 
terminal galactose. 
 
 Pentasialo Fe2-transferrin contain one biantennary, disialylated N glycan 
and one triantennary trisialylate N-glycan. The structure of monosialo-Fe2-
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transferrin, which is a part of CDT, remains unclear. The CDT isoforms can have 
either deficient or defective N glycan chains. 
 
 In contrast to other glycoproteins, lack of terminal sialic acid residues in 
the CDT isoforms does not affect hepatic clearance of CDT through the 
asialoglycoprotein receptor. 
 The plasma half life of CDT is 14 days whereas the plasma half life of 
transferrin is 7 days 72 . 
 
CDT and alcoholism: 
 Decreased sialic acid content is found in serum samples of alcoholic 
pateints. The samples showed normal transferrin isoform patterns after the 
complete removal of sialic acid residues by treatment with neuraminidase. Thus 
serum transferrin from alcoholics showed sialic acid deficient transferrin 
carbohydrate structure. 
 
 Further study revealed lack of links in N glycan chains in addition to 
absent sialic acid residues. 
 
 
 Other causes for increased CDT include fructosemia, galactosemia and in 
chronic alcoholism73-77 
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OTHER TECHNIQUES USED FOR THE DIAGNOSIS OF CONGENITAL 
DISORDER OF GLYCOSYLATION: 
 
a. Enzymatic studies: 
 Since the principal defect of CDG lies in the deficient or defective enzymes 
that are required for glycosylation, enzymatic studies confirms the subtype of 
CDG. Phosphomannomutase, the enzyme deficiency in type CDGIa can be 
measured in both fibroblast and leukocytes. However enzyme activity 
measurement in leukocytes is found to be more reliable than measuring enzyme 
activity measurement in fibroblast. This is because enzyme activity in leukocytes 
were always in an abnormal range when compared to fibroblasts that had a high 
residual enzyme activity 78. 
 
b. Mutation studies: 
 In 1997, the phosphomannomutase 2 gene was cloned and more than 50 
different mutations 79-83 was identified of which missense mutation was the 
predominant one. The most common mutations are mentioned below 84-88 
 
Gene Frequent mutations Other mutations 
PMM2 
(CDG-Ia) 
R141H,F119L,V231
M,P113L 
C9Y,D65Y,V129M,F183S,D188G,T237M,T23
7R,C241S 
MPI 
(CDG-Ib) 
M51T,S102L,D131
N,M138T,R152Q, 
R219Q, 
G250S,Y255C,1398T,R418H 
ALG6 
(CDG-Ic) 
Dutch mutation 
A333V IVS3+5G>A,S478P,F304S,∆1299 
Till date only a handful of other mutations has been identified 89-91. 
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c. Lipid Linked Oligosaccharide analysis (LLO):  
  The defects of CDGIc, Id, and Ie can be elucidated by comparing the LLO 
of yeast mutant strains with the Lipid Linked Oligosaccharide structures of 
patients. However, LLO analysis is limited to defects in the cytosol and ER.  
 
Prenatal diagnosis of CDG: 
Prenatal diagnosis for CDGIa92 is now possible due to the availability of  
a. Mapping the disease locus on chromosome 16p13  
b. Consequent identification of the enzyme defect  
c. Cloning of the PMM2 gene. 
 
 Prenatal diagnosis based on transferrin IEF in fetal blood is not reliable93,94. 
Therefore Enzyme activity measurement in cultured trophoblasts or amniocytes 
are useful but they may also be inconclusive at times 82. Therefore, in the fetus 
direct mutation analysis is preferred.  
 
 Prenatal diagnosis of CDG is possible, only if it satisfies one of the two 
below mentioned conditions 
 
1) The diagnosis has been confirmed in the index patient  
2) The mutations have been detected in the parents.  
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MANAGEMENT OF CDG 95-100: 
 At present only three forms of CDG have specific treatment. They are 
CDG-Ia, CDG-I b, CDG-IIc 
 
 CDGI-a: mannose therapy and fucose supplementation to enhance GDP-
mannose pool was not much successful. It is found that glucose starvation 
improves N-glycosylation in fibroblasts.Based on this finding research is going 
regarding the influence of ketogenic diet in CDG-Ia. Acetyl salicylic acid of 0.5 
mg/kg per day is given to symptomatic pateints to reduce stroke like events. 
Biphosphonates should be given to pateints with recurrent fractures.  
 
 CDG-Ib: Life long oral mannose supplementation at a dose of 100-150 
mg/kg/day (in 4-6 doses/day) has shown significant improvement. Serum 
mannose is maintained above 200 M. Side effects of mannose therapy such as 
osmotic diarrhoea and increase in glycosylated haemoglobin should be monitored 
carefully. 
 
 CDG-IIc: Fucose supplementation at a dose of 25mg/kg/day in three doses 
improves the fucosylation of glycoproteins and controls recurrent infections. 
 
 Though other forms of CDG has only supportive treatment at present.  
 
 Research in the field of enzyme replacement therapy and gene therapy may 
provide specific treatment for other forms of CDG in near future. 
  
Aim of the study 
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AIM AND OBJECTIVES OF THE STUDY 
1) To study Transferrin electrophoresis pattern among the apparently healthy 
control group and clinically suspected congenital glycosylation disorders 
group.  
2) To identify the prevalence of abnormal transferrin glycosylation in the 
study population 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
 The study protocol was approved by the Ethical committee, Madras 
Medical College. The copy of which is enclosed. 
 
Study design : Case control study 
Study period : January 2016 to September 2016 
 
Subject selection: 
Group 1: (Study group) 
 Samples were collected from 30 cases with clinical signs and symptoms 
strongly suspicious of congenital disorder of glycosylation. 
 
Group 2: (Control group) 
 Samples were collected from 30 individuals who are apparently healthy. 
Individuals had no signs and symptoms of congenital disorder of glycosylation 
and any other chronic illness or co morbidities. Samples for the control group 
were obtained from both paediatric and adult population irrespective of the age or 
sex of the individual since glycosylation of transferrin is not affected by age or 
sex. 
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Inclusion criteria: 
1. Individuals with clinical features of congenital glycosylation disorders 
a. Neurological signs-psychomotor retardation, ataxia, hypotonia, 
areflexia, seizures 
b. Ophthamological signs-strabismus, coloboma iris, retinopathy, optic 
atrophy 
c. Dysmorphic features-inverted nipples, cutis laxa 
d. Protein losing enteropathy 
e. Coagulopathy  
f. Hypogonadism 
g. Radiological findings-Cerebral/Cerebellar atrophy, Cerebellar 
hypoplasia  
 
3. Unexplained neurological syndrome particularly when associated with other 
organ disease. 
4. Unexplained syndrome even without neurological involvement 
 
Exclusion criteria:  
1. Children younger than one month due to the presence of maternal 
isoforms 
2. H/O alcohol intake. 
3. H/O liver cirrhosis 
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Sample collection: 
 Under strict aseptic precautions 2-3 ml of venous blood sample was 
collected in a serum separator tube. 
 
Sample preparation: 
 Serum separator tube containing the venous blood sample was allowed to 
stand for 35 minutes in order for clotting and serum to separate.  (This step is 
crucial since plasma fibrinogen interferes with the carbohydrate deficient 
transferrin assay). The sample was then centrifuged at 3000 rpm for 10 minutes. 
Serum was separated from the centrifuged sample and was stored in a 2 ml 
eppendorf tube. 
 
Sample storage: 
 Serum in the 2ml eppendorf tube was stored at – 40 degree Celsius for a 
period of not more than one month, since the stability of the sample for the assay 
is up to 30 days at -40 degree Celsius 
 
Sample analysis: 
Methodology: 
 Serum transferrin electrophoresis using Sebia’s capillary zone 
electrophoresis MINICAP system and carbohydrate deficient transferrin assay kit.  
 
 This technique separates the serum transferrin isoforms into 5 fractions 
namely: asialotransferrin disialotransferrin, trisialotransferrin, 
tetrasialotransferrin and pentasialotransferrin.  
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 The low-sialylated isoforms- disialotransferrin, monosialotransferrin and 
asialotransferrin constitutes CDT (Carbohydrate Deficient Transferrin). 
 The separated transferrin isoforms are detected and quantified at an 
absorbance of 200 nm.  
 
Principle of the test  
With this technique, charged molecules are separated by electroosmotic flow at a 
pH of 8.8 
 
 Electroosmotic flow (electro endosmosis): Capillaries are fixed with 
hydroxyl ions. Therefore the positive ions in the solution form cluster around the 
negatively charged hydroxyl ions. This creates a stern potential.The potential that 
exist between fixed and associated cloud of ions is termed as the electrokinetic 
potential/zeta potential. 
 
 On application of the current the fixed ions remain immobile whereas the 
cloud of ions move towards the oppositely charged electrode. Since the ions in 
solution are well hydrated, the solvent too moves along with the ions. The 
movement of solvent and its solutes relative to the fixed support is known as 
endosmosis which causes the preferential movement of water in one direction. 
Macromolecules in solution which move in the opposite direction will remain 
immobile or may even be swept backtowards if the charge on them is 
insufficient.As the inner surface of a glass capillary tube is coated with many 
charged groups, endosmosis is very strong. Endosmosis is the primary driving 
force for migration in the capillary electrophoresis system. 
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The MINICAP System has 2 capillaries functioning in parallel. Sample is 
diluted with the specific sample diluent and injected at the capillary’s anode 
end. A high voltage is applied for protein separation and direct detection of 
the proteins is at 200 nm at the capillary’s cathodic end. Following which the 
capillaries are washed with the wash solution.  
 
Requirement: 
1. Sebias MINICAP capillary electrophoresis system. 
2. Sebias MINICAP CDT kit. 
The kit contains: 
a. Buffer (ready to use) 2 vials, 250 mL each 
b. Sample diluent (ready to use) 1 vial, 80 mL 
c. Wash solution (stock solution) 1 vial, 25 mL 
d. CDT wash solution (ready to use) 1 vial, 80 mL 
e. Sample treatment solution. 
f. Reagent cups 1 pack of 1 25 
g. Filters 3 filters 
h. Bins for used cups 4 bins 
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Preparation of serum samples to remove interferences from 
immunoglobulins: 
 200 µL of serum is added to 50 µL of samples treatment solution (PN2054) 
provided in the kit. Vortexed for 5 seconds. It is then centrifuged for a minute at 
3000rpm. The supernatant is collected and then analyzed. 
 
Samples to avoid:  
 Hemolyzed serum samples since Hemolysis distorts the transferrin 
isoforms electrophoretic pattern. 
 Aged, improperly stored serum samples. 
 Plasma samples as Fibrinogen migrates before the asialotransferrin isoform 
and causes distortion of the electrophoretic pattern.  
 Samples that contain EDTA or citrate. 
 
PROCEDURE: 
1) Software for CDT analysis was installed.  
2) MINICAP CDT buffer was kept in position "B2" in the instrument. 
3) CDT analysis program was selected  
4) Appropriate coupling cap, pipe and filter was fixed  
5) New reagent cups was placed on the appropriate place in the loading 
system  
6) New bin for used cups was placed in the intended position.  
7) Reagent level was checked and in the window "Check reagent levels"was 
selected and updated in the software. 
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8) Samples was placed in the the rotating sampler which has 26 positions for 
sample tubes (positions No. 1 to 26)  
9) Sample diluent was placed in position No. 27on the rotating sampler 
(Diluent Solution position). 
10) Rotating sampler was slided into the MINICAP system. 
11) Doors of the MINICAP system was closed which acts as a sensor for the 
start of the analysis. 
 
Dilution - Migration - Description of the Automated steps 
1. Samples were diluted with sample diluent and the sample probe was rinsed 
after each sample. 
2. Capillaries were washed. 
3. Diluted sample was injected into capillaries. 
4. Migration was carried out under constant voltage for about 8 minutes and 
the temperature was controlled by Peltier effect. 
5. Transferrin isoforms were detected directly by scanning at 200 nm and an 
electrophoretic profile appeared on the screen of the system. 
 
Result Analysis 
 At the end of the analysis, system displayed electrophoretic pattern and 
quantified the concentration (%) of each fraction Transferrin isoforms i.e. 
pentasialotransferrin, tetrasialotransferrin, trisialotransferrin, disialotransferrin, 
asialotransferrin and CDT. 
  
Statistical Analysis 
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STATISTICAL ANALYSIS 
 
The results obtained were analysed as follows 
1. Distribution of transferrin isoforms among cases and controls 
2. Statistical significance in the distribution of asialo,mono,di,tri,tera,penta 
sialotransferrin isoforms between adult and pediatric age group  in the control 
group was analysed 
3. Statistical significane in the distribution of asialo, mono, di, tri, tera, penta 
sialotransferrin isoforms between males and females in the control group was 
analysed  
 
4. Comparision of transferrin isoforms in various clinical presentations among 
the cases. 
 Consanginous vs Non consanginous  
 Similar family history vs No similar family history, 
 Dysmorphic features vs Normal appearance, 
 Ophthalmological signs vs No ophthalmological signs 
 Radiological findings vs No radiological features 
5.  Prevalence of CDG in the study population. 
 
 Statistical analysis was done using SPSS software version 20.0 by 
Independent sample T test and Chi square test. P-value <0.05 is considered as 
statistically significant .Confidence interval 95%. 
  
Results 
  
MASTER CHART 
DISTRIBUTION OF TRANSFERRIN ISOFORMS AMONG THE CONTROLS: 
Group Age group Sex 
Asialo 
Transferrin 
(%) 
Monosialo 
Transferrin 
(%) 
Disialo 
Transferrin 
(%) 
Trisialo 
Transferrin 
(%) 
Tetrasialo 
Transferrin 
(%) 
Pentasialo 
Transferrin 
(%) 
CDT 
Transferrin 
(%) 
Control Paediatric Male 0 0 0.7 4 84.1 11.2 0.7 
Control Adult Male 0 0 0.9 1.2 80.5 17.4 0.9 
Control Adult Male 0 0 0.8 1.9 82.2 12.3 0.8 
Control Adult Female 0 0 0.7 1.5 82.6 12.3 0.7 
Control Paediatric Female 0 0 0.7 2.2 77.8 19.3 0.7 
Control Adult Female 0 0 0.4 3.7 80.4 16.3 0.4 
Control Adult Female 0 0 0.9 2.2 83.2 13.7 0.9 
Control Adult Male 0 0 0.7 2.6 81.3 15.4 0.7 
Control Paediatric Male 0 0 0.6 0.9 85 13.5 0.6 
Control Adult Female 0 0 0.6 1.6 83.1 12.6 0.6 
Control Paediatric Male 0 0 0.7 3 77.8 18.5 0.7 
Control Paediatric Female 0 0 0.8 2.3 80.7 16.2 0.8 
Control Paediatric Male 0 0 0.7 3 82.4 13.9 0.7 
Control Paediatric Female 0 0 0.6 4 74.7 20.7 0.6 
Control Adult Female 0 0 1.4 3.3 81.7 13.8 1.4 
Control Adult Male 0 0 0.5 2.6 83.4 16.5 0.5 
Control Adult Female 0 0 0.8 3.8 81.4 14 0.8 
Control Adult Female 0 0 0.4 1.5 83 15.1 0.4 
Control Paediatric Female 0 0 0.8 1.6 83 14.6 0.8 
Control Adult Male 0 0 0.6 1.7 80.3 14.7 0.6 
Control Adult Male 0 0 0.4 1.6 82.1 14.6 0.4 
Control Adult Male 0 0 1.1 1.7 81.3 16.6 1.1 
Control Adult Male 0 0 1 2.6 82.8 13.6 1 
Control Adult Male 0 0 0.4 2.7 82.8 14.1 0.4 
Control Adult Female 0 0 0.6 1.9 80.7 13.5 0.6 
Control Paediatric Male 0 0 0.9 2.8 80.5 15.8 0.9 
Control Adult Male 0 0 0.8 2.7 82.8 15.7 0.8 
Control Adult Female 0 0 0.9 2.8 81.3 15 0.9 
Control Paediatric Female 0 0 1 2.7 80.3 16 1 
Control Paediatric Male 0 0 1.1 2.9 80.1 15.9 1.1 
DISTRIBUTION OF TRANSFERRIN ISOFORMS AMONG THE CASES: 
Group 
Asialo  
Transferrin 
(%) 
Monosialo  
Transferrin 
(%) 
Disialo  
Transferrin 
(%) 
Trisialo  
Transferrin 
(%) 
Tetrasialo  
Transferrin 
(%) 
Pentasialo  
Transferrin 
(%) 
CDT  
Transferrin 
(%) 
Cases 6.6 0 0.9 1.7 77.8 13 7.5 
Cases 0 0 0.7 0.7 84.9 13.7 0.7 
Cases 0 0 0.7 2.7 82.4 14.2 0.7 
Cases 0 0 1 3.4 82.6 13 1 
Cases 0 0 0.5 3.6 84 11.9 0.5 
Cases 0 0 0.7 1.4 79.9 18 0.7 
Cases 0 0 0.5 1.1 83.7 14.7 0.5 
Cases 0 0 0.5 1.5 81.5 16.5 0.5 
Cases 13.8 0.3 52.6 2.7 24.4 6.2 66.4 
Cases 0 0 0.5 2.8 82.8 13.9 0.5 
Cases 0 0 0.8 1.9 82 15.3 0.8 
Cases 0 0 0.3 4.1 79.2 16.4 0.3 
Cases 0 0 0.8 2.7 82.7 13.8 0.8 
Cases 0 0 0.9 0.2 75.7 23.2 0.9 
Cases 10.2 0.2 46.2 2.4 31.9 9.1 56.4 
Cases 0.4 0 0.4 1.2 81.2 16.8 0.8 
Cases 0 0 0.6 3.1 86.2 10.1 0.6 
Cases 0 0 0.7 3 83.6 12.7 0.7 
Cases 0 0 1.1 0.8 82.2 15.9 1.1 
Cases 0 0 1.1 1 79.1 18.8 1.1 
Cases 0 0 0.6 1.1 81.3 17 0.6 
Cases 0 0 0.6 3.9 82.9 12.6 0.6 
Cases 0 0 0.7 0.8 81.3 17.2 0.7 
Cases 0 0 0.5 1.7 84.1 13.7 0.5 
Cases 0 0 0.3 3.2 79.2 17.3 0.3 
Cases 0 0 0.9 1.8 82.9 14.4 0.9 
Cases 0 0 0.7 3 82.7 13.6 0.7 
Cases 0 0 0.8 1.4 81.4 16.4 0.8 
Cases 0 0 0.5 4.9 80 14.6 0.5 
Cases 0 0 0.8 3.9 79.7 15.6 0.8 
 
DISTRIBUTION OF CLINICAL FEATURES AMONG CASES: 
Group Age Group of children Sex 
Consanginous 
Marriage 
Family 
H/O 
Neurological 
Signs 
Dysmorphic 
Features 
Ophthalmological 
Signs 
Radiological 
Findings 
Other 
Features 
Cases Paediatric Female Yes No Yes No No Yes No 
Cases Paediatric Female No No Yes No No No No 
Cases Paediatric Male Yes No Yes No No No No 
Cases Paediatric Male No No Yes No No No No 
Cases Paediatric Female Yes No Yes No No No No 
Cases Paediatric Male Yes No Yes No No No No 
Cases Paediatric Female No Yes Yes No No No Yes 
Cases Paediatric Female No No Yes No Yes No No 
Cases Paediatric Male Yes No Yes No No Yes No 
Cases Paediatric Male No No Yes Yes Yes No No 
Cases Paediatric Female No Yes Yes Yes No Yes No 
Cases Paediatric Male No No Yes Yes No Yes No 
Cases Paediatric Male Yes No Yes Yes Yes Yes No 
Cases Paediatric Female Yes Yes Yes No Yes No No 
Cases Paediatric male Yes No Yes No No Yes No 
Cases Paediatric Male No No Yes Yes No Yes No 
Cases Paediatric Female No No Yes Yes Yes Yes No 
Cases Paediatric Male No Yes Yes No Yes No No 
Cases Paediatric Male Yes No Yes Yes Yes No No 
Cases Paediatric Male Yes No Yes No No No No 
Cases Paediatric Male Yes No Yes Yes No Yes No 
Cases Paediatric Female No Yes Yes No Yes No No 
Cases Paediatric Female No Yes Yes Yes No No No 
Cases Paediatric Male No Yes Yes Yes No No No 
Cases Paediatric Male No Yes Yes Yes No No No 
Cases Paediatric Male Yes No Yes No No Yes No 
Cases Paediatric Male No No Yes No No Yes No 
Cases Paediatric Male No No Yes No Yes No No 
Cases Paediatric Male Yes No Yes Yes No No No 
Cases Paediatric Male No Yes Yes Yes Yes No No 
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RESULTS 
 
 Distribution  of transferrin isoforms among cases and control: 
 
 
TABLE 1: 
 
 
  
  
Transferrin isoforms Group N Mean (%) 
Std. 
Deviation 
Std. Error 
Mean 
Asialotransferrin 
Cases 30 1.0 3.24 .59 
Control 30 0 0 0 
Monosialotransferrin 
Cases 30 .01 .06 .01 
Control 30 0 0 0 
Disialotransferrin 
Cases 30 3.93 12.39 2.26 
Control 30 .75 .23 .04 
Trisialotransferrin 
Cases 30 2.25 1.20 .21 
Control 30 2.43 .83 .15 
Tetrasialotransferrin 
Cases 30 78.11 13.79 2.51 
Control 30 81.44 2.06 .37 
Pentasialotransferrin 
Cases 30 14.65 3.14 .57 
Control 30 15.09 2.09 .38 
CDT 
Cases 30 4.96 15.44 2.82 
Control 30 .75 .23 .04 
 
Figure 13: Comparision of transferrin isoforms among the cases and controls  
 
 
 
 The above figure illustrates that the Asialo, Disialo and CDT isoforms are 
higher in the cases group when compared to the control group.  
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 Distribution of transferrin isoforms among controls: 
 
TABLE 2: 
 
 
 
Thus the mean (SD) of tranferrin isoforms among the controls were estimated 
and found to be Asialo transferrin-0 (0); monosialo transferrin- 0(0); disialo 
transferrin-0.75% (0.2) ; trisialotransferrin- 2.4% (0.8)  ; tetrasialotransferrin- 81.4 
% (2) ; pentasialotransferrin- 15.09% (2) and CDT-0.75% (0.2).  
  
Transferrin N Minimum (%) 
Maximum 
(%) 
Mean 
(%) 
Std. 
Deviation 
Asialo 30 0 0 0 0 
Monosialo 30 0 0 0 0 
Disialo 30 0.4 1.4 0.75 0.23 
Trisialo 30 0.9 4.0 2.43 0.83 
Tetrasialo 30 74.7 85.0 81.44 2.06 
Pentasialo 30 11.2 20.7 15.09 2.09 
CDT 30 0.4 1.4 0.75 0.23 
      
Figure 14: Distribution of transferrin isoforms among control group  
 
 
 Asialotransferrin and monosiaotransferrin was found to be absent in the 
control group.Distribution of disialotransferrin was 1%, trisialotransferrin was 
2%, tetrasialotransferrin was 81% and pentasialotransferrin was 15% among the 
control group.  
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 Statistical significance in the distribution of transferrin isoforms between 
adult and pediatric age group in controls: 
 
 Among the control group 11 were pediatric samples and 19 were adult 
samples. Transferrin isoform distribution between the adult and pediatric age 
group was studied in the control group 
 
TABLE 3: 
 
   
 
TABLE 4: Independent sample T test 
 
Transferrin Age Group of children N 
Mean 
(%) 
Std. 
Deviation P value 
Asialo Peadiatric 11 0 0(a) - Adult 19 0 0(a) 
Monosialo Peadiatric 11 0 0(a) - Adult 19 0 0(a) 
Disialo Peadiatric 11 0.78 0.16 0.578 Adult 19 0.73 0.26 
Trisialo Peadiatric 11 2.67 0.91 0.236 Adult 19 2.29 0.76 
Tetrasialo Peadiatric 11 80.58 3.02 0.082 Adult 19 81.94 1.03 
Pentasialo Peadiatric 11 15.96 2.73 0.084 Adult 19 14.58 1.48 
CDT Peadiatric 11 0.78 0.16 0.578 Adult 19 0.73 0.26 
(a) t cannot be computed because the standard deviations of both are zero 
 
 It was found that no statistical significant difference occurs in the 
distribution of transferrin isoforms between the paediatric and adult population. 
Age Group of controls Frequency Percent 
Peadiatric 11 36.7 
Adult 19 63.3 
Total 30 100.0 
. 
 
Figure 15: Distribution of transferrin isoforms between paediatric and adult 
population in control group 
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 Statistical significance in the distribution of transferrin isoforms between 
males and females in controls: 
 
 Among the control group 16 were males and 14 were females. Transferrin 
isoform distribution between the males and females was studied in the control 
group 
 
TABLE 5: 
 
 
TABLE 6:  Independent sample T test 
 
Transferrin Sex N Mean (%) Std. Deviation P value 
Asialo Male 16 0 0(a) -  Female 14 0 0(a) 
Monosialo Male 16 0 0(a) -  Female 14 0 0(a) 
Disialo Male 16 0.74 0.21 0.878  Female 14 0.75 0.25 
Trisialo Male 16 2.36 0.79 0.657  Female 14 2.50 0.89 
Tetrasialo Male 16 81.83 1.76 0.660  Female 14 80.99 2.34 
Pentasialo Male 16 14.98 1.88 0.760  Female 14 15.22 2.38 
CDT Male 16 0.74 0.21 0.878  Female 14 0.75 0.25 
(a) t cannot be computed because the standard deviations of both are zero 
 
 It was found that no statistical significant difference occurs in the 
distribution of transferrin isoforms between the male and female population in the 
control group. 
Sex of controls Frequency Percent 
Male 16 53.3 
Female 14 46.7 
Total 30 100.0 
  
Figure 16: Distribution of transferrin isoforms between males and females in 
the control group 
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 Distribution of transferrin isoforms in cases: 
TABLE 7: 
  
 
 
 Thus the mean (SD) of tranferrin isoforms among the cases were estimated 
and found to be Asialo transferrin-1.03% (3.24); monosialo transferrin- 0.01% 
(0.06); disialo transferrin-3.93% (12.39) ; trisialotransferrin- 2.25% (1.24)  ; 
tetrasialotransferrin- 78.11 % (13.79) ; pentasialotransferrin- 14.65 % (3.14) and 
CDT-4.96% (15.44)  
  
Transferrin N Minimum (%) 
Maximum 
(%) 
Mean 
(%) 
Std. 
Deviation 
Asialo 30 .0 13.8 1.03 3.24 
Monosialo 30 .0 0.3 0.01 0.06 
Disialo 30 .3 52.6 3.93 12.39 
Trisialo 30 .2 4.9 2.25 1.24 
Tetrasialo 30 24.4 86.2 78.11 13.79 
Pentasialo 30 6.2 23.2 14.65 3.14 
CDT 30 .3 66.4 4.96 15.44 
      
Figure 17: Distribution of transferrin isoforms among cases  
 
 
 Distribution of transferrin isoforms among various presenting featrures 
in cases  
Figure 18: Distribution of presenting features among cases  
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Consanguinous marriage 
 The 30 cases were divided into two groups i.e. the group with H/O 
consanguinous marriage in parents and the group with no H/O consanguinous 
marriage in parents. 
 
 Among the 30 pediatric samples obtained for cases, 13 had consanguinity 
and 17 were non non consanginous. 
 
TABLE 8 : 
 
Consanguinous Marriage Frequency Percent 
Yes 13 43.3 
No 17 56.7 
Total 30 100.0 
 
 
  
The figure illustrates that the percentage of asialo transferrin, disialotransferrin 
and CDT are increased in the group with history of consanginous marriage when 
compared to the group with no history of consanginous marriage 
 
  
Figure 19: frequency of consanguinity and nonconsanguinity among cases 
  
 
 
 
 
Figure 20:  Distribution of transferrin isoforms between the group with 
history of consanguinous marriage and history of non consanguinous 
marriage in parents. 
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TABLE 9:   Independent sample T test 
 
 
 
Consan 
ginous N 
Mean 
(%) 
Std. 
Deviation 
Std. 
Error 
Mean 
P 
value 
Asialotransferrin Yes 13 2.35 4.70 1.30 0.050* No 17 .02 0.09 0.02 
Monosialotransferrin Yes 13 .03 0.09 0.02 0.108 No 17 0 0 0 
Disialotransferrin Yes 13 8.26 18.30 5.07 0.094 No 17 0.61 0.19 0.04 
Trisialotransferrin Yes 13 2.07 1.27 0.35 0.483 No 17 2.39 1.15 0.28 
Tetrasialotransferrin Yes 13 72.63 19.93 5.52 0.056 No 17 82.29 1.92 0.46 
Pentasialotransferrin Yes 13 14.62 4.30 1.19 0.964 No 17 14.67 1.99 0.48 
CDT Yes 13 10.62 22.70 6.29 0.079 No 17 0.63 0.18 0.04  
 
 Transferrin isoform distribution was studied between the two groups. It 
was found that statistical significant differrence occurs in the distribution of asialo 
transferrin between the two groups. 
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Family history: 
 The 30 pediatric samples obtained for cases were divided into two groups 
i.e. the group with similar history in the family and the group with no similar 
family history. 
 
TABLE 10: 
 
 
TABLE 11:   Independent sample T test 
 
 familyhistory N Mean (%) 
Std. 
Deviation 
Std. 
Error 
Mean 
P 
value 
asialotransferrin Yes 9 0 0 0 0.261 No 21 1.47 3.82 0.83 
monosialotransferrin Yes 9 0 0 0 0.365 No 21 0.02 0.07 0.01 
disialotransferrin Yes 9 0.64 0.18 0.06 0.351 No 21 5.33 14.68 3.20 
trisialotransferrin Yes 9 2.18 1.36 0.45 0.844 No 21 2.28 1.15 0.25 
tetrasialotransferrin Yes 9 81.35 2.74 0.91 0.408 No 21 76.71 16.30 3.55 
pentasialotransferrin Yes 9 15.81 3.25 1.08 0.191 No 21 14.15 3.03 0.66 
CDT Yes 9 0.64 0.18 0.06 0.325 No 21 6.81 18.27 3.98s 
 
Transferrin isoform distribution was studied between the two groups. It was found 
that no statistical significant differrence occurs in the distribution of transferrin 
isoforms between the two groups. 
 
Family H/O 
 Frequency Percent 
Valid No 21 70.0 
 Yes 9 30.0 
 Total 30 100.0 
 
 
Figure 21: frequency of similar family history and no similar family history 
in the cases 
 
 
 
Figure 22:   Distribution of transferrin isoforms between cases with similar 
family history and cases with no similar family history  
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TABLE 12:  Neurological Signs 
 
Neurological Signs Frequency Percent 
 Yes 30 100.0 
 
 
 Of the 30 samples obtained for screening, all the patients presented with 
variety of neurological manifestations among which seizures, mental retardation, 
developmental delay and hypotonia were the most common clinical symptoms. 
 
Dysmorphic Features 
 The 30 pediatric samples obtained for cases were divided into two groups 
i.e. the group with dysmorphic features and the group with no dysmorphic 
features. 
 
TABLE 13: 
 
Dysmorphic Features Frequency Percent 
 No 17 56.7 
 Yes 13 43.3 
 Total 30 100.0 
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TABLE 14:  Independent sample T test 
 
 Dysmorphic N Mean (%) 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
P value 
Asialotransferrin Yes 13 0.03 0.11 0.03 0.142 
No 17 1.80 4.20 1.019 
Monosialotransferrin Yes 13 0 0 0 0.224 
No 17 0.02 0.08 0.02 
Disialotransferrin Yes 13 0.60 0.22 0.06 0.204 
No 17 6.47 16.19 3.92 
Trisialotransferrin Yes 13 2.47 1.34 0.37 0.389 
No 17 2.08 1.08 0.26 
Tetrasialotransferrin Yes 13 81.68 2.01 0.55 0.220 
No 17 75.37 17.98 4.36 
pentasialotransferrin Yes 13 15.20 2.01 0.55 0.414 
No 17 14.23 3.79 0.92 
CDT Yes 13 0.63 0.22 0.06 0.185 
No 17 8.27 20.14 4.88 
 
Transferrin isoform distribution was studied between the two groups.  
 
 
 Transferrin isoform distribution was studied between the two groups. It 
was found that no statistical significant differrence occurs in the distribution of 
transferrin isoforms between the two groups. 
 
  
Figure 23: frequency of dysmorphic features and no dysmorphic features in 
cases  
 
 
 
 
Figure 24: Distribution of transferrin isoforms between the group with 
dysmorphic features and the group with no dysmorphic features in cases. 
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Ophthalmological Signs: 
 The 30 pediatric samples obtained for cases were divided into two groups 
i.e. the group with ophthalmological signs and the group with no 
ophthalmological signs. 
 
TABLE 15: 
 
TABLE 16:  Independent sample T test 
 
 ophthal N 
Mea
n 
Std. 
Deviation 
Std. 
Error 
Mean 
P 
value 
Asialotransferrin Yes 10 0 0 0 0.224 No 20 1.55 3.90 0.87 
Monosialotransferri
n 
Yes 10 0 0 0 0.328 No 20 0.02 0.07 0.01 
Disialotransferrin Yes 10 0.73 0.18 0.05 0.326 No 20 5.53 15.04 3.36 
Trisialotransferrin Yes 10 2.33 1.28 0.40 0.818 No 20 2.22 1.19 0.26 
Tetrasialotransferri
n 
Yes 10 81.87 2.74 0.86 0.299 No 20 76.23 16.59 3.71 
pentasialotransferri
n 
Yes 10 15.07 3.50 1.10 0.616 No 20 14.44 3.01 0.67 
CDT Yes 10 0.73 0.18 0.05 0.297 
 No 20 7.0800 18.71100 4.18391  
 
Transferrin isoform distribution was studied between the two groups. It was found 
that no statistical significant differrence occurs in the distribution of transferrin 
isoforms between the two groups. 
 
 
 
Ophthalmological Signs Frequency Percent 
 No 20 66.7 
 Yes 10 33.3 
 Total 30 100.0 
  
Figure 25: frequency of ophthalmological signs and no ophthalmological 
signs in cases 
 
 
 
 
Figure 26: Distribution of transferrin isoforms between the group with 
ophthalmological and the group with no ophthalmological signs 
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Radiological Findings 
 The 30 pediatric samples obtained for cases were divided into two groups 
i.e. the group with radiological finding and the group with no radiological finding. 
 
TABLE 17: 
Radiological Findings Frequency Percent 
 No 19 63.3 
 Yes 11 36.7 
 Total 30 100.0 
 
TABLE 18: Independent sample T test 
 Radiological features N 
Mean 
(%) 
Std. 
Devia 
tion 
Std. Error 
Mean 
P 
value 
Asialotransferrin Yes 11 2.81 5.00 1.51 0.019* No 19 0 0 0 
Monosialotransfe
rrin 
Yes 11 0.04 0.10 0.03 0.063 No 19 0 0 0 
Disialotransferri
n 
Yes 11 9.52 19.76 5.95 0.058 No 19 0.68 0.22 0.05 
Trisialotransferri
n 
Yes 11 2.33 0.90 0.27 0.787 No 19 2.21 1.36 0.31 
Tetrasialotransfe
rrin 
Yes 11 72.02 21.86 6.59 0.065 No 19 81.63 2.26 0.51 
pentasialotransfe
rrin 
Yes 11 13.24 3.45 1.04 0.060 No 19 15.46 2.70 0.62 
CDT Yes 11 12.34 24.44 7.36 0.044* No 19 0.68 0.22 0.05 
 
 Transferrin isoform distribution was studied between the two groups. It 
was found that statistical significant differrence occurs in the distribution of 
asialotransferrin isoform and CDT between the two groups. 
 Figure 27: frequency of radiological findings and no radiological findings in 
cases 
  
 
 
 
Figure 28: Distribution of transferrin isoforms between the group with 
radiological findings and the group with no radiological findings in the cases 
group 
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7. Prevalence of CDT positive samples among cases: 
TABLE 19:    (chi square test) 
CDT No of cases Percent % P value 
High 3 10% 
<0.001** 
Normal 27 90 % 
Total 30 100  
 
 
The findings shows that among 30 cases evaluated for screening, three cases has 
showed increased carbohydrate deficient transferrin isoform (asialo and disialo 
transferrin). Thus in this study we have detected a prevalence of 10% CDG among 
the 30 patients which is statistically highly significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Prevalence of CDG among cases 
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DISCUSSION 
 
 Glycoproteins play multiple significant roles in cell biology. Defect in the 
glycosylation pattern of glycoproteins affect their function and leads to a group of 
disease known as congenital disorders of glycosylation. The basic defect in this 
disorder is a mutant gene which encodes the enzymes responsible for 
glycosylation of glycoproteins. In the study on CDG by Jaeken in 2001 a 
prevalence of 1 in 20,000 worldwide101 has been reported.In our country no 
formal study on prevalence of CDG has been undertaken to our knowledge.There 
are also no reports about any study or case report of CDG case among Indians in 
reputed journals.Hence we are unable to compare population prevalence of CDG. 
 
 CDG presents with a broad clinical features affecting multiple organ 
systems in the body (especially the nervous system, muscles, intestines & immune 
system). Moreover the range of severity of this disorder is also very wide i.e. 
CDG can be very mild so that the patient is asymptomatic or it can also be fatal 
leading to death. There is also lack of awareness and access to the laboratory 
techniques available to evaluate this disorder. All these factors make it difficult 
for the clinicians in diagnosing this disorder. 
 
 Though CDG is a disorder with broad clinical presentation, neurological 
manifestations such as seizure disorder, delayed milestones and mental retardation 
are the most common presentations. CDG being an autosomal recessive condition 
which runs in families, consanguinous marriage remains to be a significant risk 
factor for the inheritance of this disorder.  
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 Since consanguinous marriage and neurological symptoms like seizures are 
more prevalent in our population, this study aimed to screen for CDG in our 
population using capillary zone electrophoresis of serum transferrin. Although 
glycosylation pattern of other glycoproteins can be studied, transferrin is the 
preferred glycoprotein because it is the most abundant glycoprotein in serum and 
the glycosylation of this glycoprotein does not change with age when compared to 
other glycoproteins. 
 
 The gold standard technique for the diagnosis of CDG is isoelectric 
focussing of serum transferrin which is a cumbersome manual technique. 
Therefore we have chosen capillary zone electrophoresis of serum transferrin 
which is an automated precise technique to screen this disorder. 
 
 In this study control samples were obtained from apparently healthy 
normal individuals of varying sexes and age groups after ruling out the history of 
alcoholism since chronic alcoholism interferes with the CDT assay. 
 
 Samples for cases were obtained from pediatric patients who were 
clinically suspected to suffer from CDG. Other differential diagnosis such as 
inborn error of aminoacid metabolism, fatty acid oxidation defects,structural 
anomalies of brain were excluded by the possible investigations such as urine  
metabolic screening, tandem mass spectrometry analysis of dried blood spot for 
detection of disorders of amino acids/fattyacid oxidation defects/ organic 
acidemias ,CT brain, ophthalmological and ENT evaluation. In such patients 
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whose diagnosis still remained inconclusive but the clinical symptoms were 
suggestive of CDG were screened by CZE of serum transferrin to find the 
prevalence of the disease.   
 
 Out of 30 cases screened for CDG using CZE three cases showed abnormal 
transferrin glycosylation pattern.The pattern is similar to the pattern “A” reported 
by Fabiene (most frequent pattern in CDG) which is consistent with the complete 
loss of glycans. Thus the prevalence of CDG is 10% among 30 cases. 
Transferrin glycosylation pattern of 30 controls were evaluated. Transferrin 
isoform distribution was compared between adult and pediatric age group & 
between males and females.It is found that there is no statistical significance 
occurs in the distribution of transferrin isoforms between the different age groups 
and sexes in the control group. 
 
 Based on clinical features the cases were divided into different groups and 
the transferrin glycoforms were compared between the groups.The groups are  
 
1. Consangineous marriage Vs non consangineous marriage 
2. Ophthalmological signs Vs no ophthalmological signs   
3. Dysmorphic features Vs no dysmorphic features 
4. Similar family history Vs no similar family history 
5. Radiological findings Vs no radiological findings 
6. Other clinical features Vs no other clinical features 
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 It was found that there is statistically significant increase of asialo 
transferrin isoform in the consangineous marriage group when compared to the 
non consanginous marriage group. As asialotransferrin contributes to the measure 
of CDT, this finding concludes that consanginous marriage is a significant risk 
factor for CDG. 
 
 Simillarly a significant statistical difference is found in the distribution of 
asialotransferrin isoforms and CDT in the group with positive radiological finding 
(cerebral atrophy) when compared to the group with no radiological finding. 
Therefore radiological evidence adds as supportive evidence in the diagnosis of 
CDG. 
Other methods available for diagnosis of  CDG: 
CDT Methods Separation Principle Glycoform Detection Method 
IEF Charge separation 
i.Electrotransfer,immunoblot,detection 
with secondary antibody 
ii.Coomassie blue staining 
CDTect Charge separation RIA of resolved fractions 
%CDT TIA Charge separation 
Immunoturbidimetry of resolved 
fractions 
CE Charge separation O.D. at 214nm 
HPLC Charge separation O.D. at 640 nm 
Electrospray mass 
spectrometry Protein size 
Summations of ions of a charged 
protein 
 
 
 
 
  
Figure 30: Serum Transferrin electrophoresis pattern of 3 cases with elevated 
CDT in our study population: 
 
Transferrin isoforms Percentage (%) Normal range % 
Asialo transferrin 6.6 <0.5 
Monosialotransferrin 0.0 <0.9 
Disialotransferrin 0.9 <2.5 
Trisialotransferrin 1.7 4.5 – 9.0 
Tetrasialotransferrin 77.8 64.8-80.0 
Pentasialotransferrin 13 12.0-18.0 
CDT 7.5 <1.3 
 
  
Transferrin isoforms Percentage (%) Normal range % 
Asialo transferrin 10.2 <0.5 
Monosialotransferrin 0.2 <0.9 
Disialotransferrin 46.2 <2.5 
Trisialotransferrin 2.4 4.5 – 9.0 
Tetrasialotransferrin 31.9 64.8-80.0 
Pentasialotransferrin 9.1 12.0-18.0 
CDT 56.4 <1.3 
 
  
  
Transferrin isoforms Percentage (%) Normal range % 
Asialo transferrin 13.8 <0.5 
Monosialotransferrin 0.3 <0.9 
Disialotransferrin 52.6 <2.5 
Trisialotransferrin 2.7 4.5 – 9.0 
Tetrasialotransferrin 24.4 64.8-80.0 
Pentasialotransferrin 6.2 12.0-18.0 
CDT 66.4 <1.3 
  
80 
 
Arndt states that “Increased fractions of trisialotransferrin in Arginosuccinate 
lyase deficiency/urea cycle disorder(prevalence 1 in 35,000) patients appear to 
interfere with CDT analysis by the  %CDT TIA assay. This can give false­positive 
CDT results. %CDT TIA assay should no longer be used for CDT measurement 
without confirmatory analysis by HPLC or capillary electrophoresis” 102,103 
 
 Study conducted by Quintana states that “measurement of transferrin 
isoforms and interpretation using method­specific reference values in HPLC and 
CZE  may offer some advantages for the diagnosis of CDG as compared with the 
standard IEF procedure” 104 
 Fabienne Parente states that “Capillary zone electrophoresis of serum 
transferrin is an alternaive technique which can be used to screen the patients 
suspected with CDG”70.  
 Fabienne Parente in the journal of Clinica Chimica Acta november 2010 
conducted a study to evaluate the CZE in screening CDG , two types of pattern 
were obtained from CDG confirmed cases in his study.They were pattern A and 
pattern B70 . Pattern A showed a characteristic decrease of penta and tetra and an 
increase of di and asialotransferrins, consistent with a loss of complete glycans   
Pattern B which showed a characteristic decrease of penta and tetra & increase of 
trisialotransferrins consistent with structurally abnormal glycans. 
  
 But CZE techniqe has limitations such as interferences from hemoglobin, 
fibrinogen, transferrin polymorphisms, complement fraction C3b & monoclonal 
immunoglobulins. 
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 Parente study states that “There is no statistically significant difference 
between the different age groups (0–5, 6–11, 12–15, 16–18, and >18y) or between 
sexes for transferrin isoforms. Reference intervals obtained at 95% confidence 
interval was 5-sialo: 12.9 to 32.4 4-sialo: 65.9 to 82.9, 3-sialo: 0.4 to 5.6, CDT (di, 
mono,asialo):0.0 to 1.3”70 
 
 Briones study states that “Congenital disorders of glycosylation (CDG) and 
mitochondrial diseases are multisystem disorders with clinical characteristics that 
may overlap. As the search for the primary defect in mitochondrial diseases is 
often unsuccessful, the pool of mitochondrial patients that remain without definite 
diagnosis might include CDG cases. Routine screening for CDG may avoid 
precocious invasive investigation” 105 . 
 
 Charge difference in transferrin may occur because of amino acid 
polymorphisms and completeness of iron saturation which can affect the 
electrophoretic pattern of capillary zone electrophoresis. Sample pretreatment 
with iron eliminates the bias due to charge differenc caused by incomplete iron 
saturation.But the interference due to aminoacid polymorphism cannot be avoided 
in capillary zone electrophoresis.   
 
Thus the advantage in using MS is that 106  
 Transferrin does not have to be saturated with iron before analysis of the 
specimen since only apotransferrin is detected and Amino acid sequence 
polymorphisms also does not interfere with the MS resolution.  
Summary & Conclusion 
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SUMMARY AND CONCLUSION 
 
 Congenital disorder of glycosylation is an inborn error of metabolism due 
to defective glycosylation of glycoproteins/glycolipids.It is a multisystem disorder 
with wide range of clinical presentations thereby making the clinical diagnosis 
difficult. Hence  the diagnosis of CDG is entirely based upon laboratory 
investigations.Since CDG is a disorder due to defective glycosylation of 
glycoproteins, glycosylation pattern of a glycoprotein should be evaluated to 
diagnose this disorder.Transferrin is a glycoprotein whose glycosylation pattern 
does not change with age when compared to other glycoproteins. Therefore 
isoelectric focussing of serum transferrin is a gold standard technique to diagnose 
this disorder.  
 
 CDG prevalence is undoubtedly underestimated in our population due to 
lack of awareness and availability of automated, quick access diagnostic 
techniques. 
 
 Since about 2 % of human genome encodes proteins for Glycosylation it is 
likely that more disorders and more affected individuals will be found as 
awareness and diagnostic testing methods improve. 
 
 This study consisted of two groups. Control group with 30 samples of 
apparently healthy individuals and cases group with 30 patients who were 
clinically suspected to have congenital disorder of glycosylation. Other 
differential diagnosis of their symptoms were excluded using possible 
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investigations such as Urine metabolic screening, Tandem mass spectrometry for 
detection of disorders of amino acids/fattyacid oxidation defects /organic 
acidemias, CT-Brain, ophthalmological and ENT evaluation. The cases were then 
screened for congenital disorder of glycosylation using capillary zone 
electrophoresis of serum transferrin.  
 
 Out of 30 cases three patients had abnormal transferrin pattern  i.e. CDT- 
7.5%, 66.4%  , 56.4 %. (The reference interval of CDT is <1.3%) . All three 
abnormal transferrin patterns observed in our study are consistent with the 
complete loss of glycans as demonstrated in the studies conducted by Fabienne 
parente. 
 
 This observational study concludes that the prevalence of CDG is about 
10% among the 30 cases which is a statistically significant finding. This finding 
inferes that the prevalence of CDG is abnormally high in the study population.  
Capillary zone electrophoresis of serum transferrin can be used as a simple 
technique to screen for this disorder. 
 
 The distribution of transferrin isoforms among different age group and 
sexes were analysed in the control group and it is found that there is no statistical 
significant difference in the distribution of transferrin isoforms between different 
age group and sexes. This finding concludes that the distribution of transferrin 
isoforms are independent of the age and sex. Therefore age and gender specific 
reference interval for transferrin isoforms may not be important in the diagnosis of 
CDG. 
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 The distribution of transferrin isoforms among various clinical 
presentations in the study group was analysed and it is found that statistically 
significant increase in the aisialotransferrin isoform is present in the group with 
History  of consangineous marriage when compared to the group with  
nonconsangineous marriage.Since asialo transferrin contributes to the 
Carbohydrate Deficient Transferrin measure, this finding infers that 
consangineous marriage is a significant risk factor for congenital disorder of 
glycosylation.  
 
 Similarly the transferrin pattern was compared between cases with positive 
radiological findings (cerebral atrophy) and cases with absent radiological 
findings.It is found that statistical significant difference exist in the distribution of 
asialotransferrin isoforms and CDT between the two groups. This finding infers 
that presence of radiological features adds as a supportive evidence for the 
diagnosis of CDG.  
 
Thus this study concludes that: 
 From this study we have first reported the presence of congenital disorder 
of glycosylation in our country. 
 The prevalence of congenital disorder of glycosylation is high in study 
group (10%). 
 Capillary zone electrophoresis of serum transferrin can be used as a reliable 
screening technique to screen this disorder in our population 
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 Age and gender specific reference interval for transferrin isoforms may not 
be important in the diagnosis of CDG. 
 Consangineous marriage is a significant risk factor for congenital disorder 
of glycosylation.  
 Radiological finding of cerebral atrophy serves as a supportive evidence 
for the diagnosis of CDG. 
 
  
Limitations of the study 
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LIMITATIONS OF THE STUDY 
 
1) Diagnosis of CDG was based upon the reference interval obtained from 
western studies. No reference interval was established in the study population 
2) 2. Accuracy and the precision of the Sebia Capillarys system for the 
quantification of   the transferrin glycoforms was not assessed  
3) Capillay zone electrophoresis was not compared and correlated with the gold 
standard technique of isoelectric focussing of serum transferrin 
4) This methodology is only a screening test for CDG . Interferences from 
hemoglobin, fibrinogen, transferrin polymorphisms, complement fraction C3b 
& monoclonal immunoglobulins need to be eliminated by using the gold 
standard IEF technique. 
5) O linked glycosylation disorders of CDG cannot be diagnosed using 
transferrin capillary zone electrophoresis 
 
  
Future scope of the study 
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FUTURE SCOPE OF THE STUDY 
 
 Reference interval for CDT glycoforms using capillary zone electrphoresis 
technique should be established in our population. 
 A Panel of tests including capillary zone electrophoresis and other tests to 
screen CDG should be structred and evaluated to screen this disorder. 
 Apo C-III analysis should be included in the panel for diagnosis of       O-
Linked CDG. 
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Annexures 
PROFORMA 
Name :                                  Age / Sex :                                             Patient ID: 
Contact details: 
 
H/O consanguineous marriage of the parents :                                                   Pedigree 
chart: 
 
H/O similar illness in the family : 
 
Significant past medical history : 
 
Any H/O chronic drug intake: 
 
Clinical features Present  Absent 
1.Neurological signs 
a. psychomotor retardation,  
b. ataxia,         
c. hypotonia, 
d. areflexia, 
e. seizures 
 
  
2. Dysmorphic features 
a. Facial dysmorphism 
b. inverted nipples 
c. cutis laxa 
 
  
Investigations done: 
UMS: 
TMS: 
CT Brain 
Ophthalmological evaluation: 
ENT evaluation: 
 
 
Serum transferrin electrophoresis pattern: 
 
  
 
  
 3.ophthamological signs 
 a. strabismus 
 b. coloboma iris 
 c. retinopathy 
 d. optic atrophy  
  
 4.Radiological findings  
 a. Cerebral/Cerebellar atrophy, 
 b. Cerebellar hypoplasia  
  
5.  Coagulopathy (blood group)   
6.  protein losing enteropathy    
7. Hypogonadism 
 
  
INFORMATION SHEET 
 
Title of the study: “A STUDY ON GLYCOSYLATION PATTERN OF SERUM 
TRANSFERRIN IN PATIENTS WITH CLINICALLY SUSPECTED CONGENITAL 
GLYCOSYLATION DISORDERS”  
Name        :       Date   : 
Age        :       OP No   : 
Sex        :       Project Patient No : 
Institution : 
 
 Your venous blood sample of 5ml has been accepted. 
 The purpose of this study is to evaluate the use of transferrin electrophoresis in the 
diagnosis of congenital glycosylation disorder. 
 We are selecting certain cases and if your blood sample is found eligible, we may be 
using your blood sample to perform extra tests and special studies which in any way 
do not affect your final report or management. 
 The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management 
or treatment. 
 
 
 Signature of Investigator    Signature of  Participant / Parent 
PATIENT CONSENT FORM 
 
Title of the study: “A STUDY ON GLYCOSYLATION PATTERN OF SERUM 
TRANSFERRIN IN PATIENTS WITH CLINICALLY SUSPECTED CONGENITAL 
GLYCOSYLATION DISORDERS”  
 
Name       :        Date  : 
Age       :        OP No  : 
Sex       :            Project Patient No : 
Address     :                                                                                              Institution: 
 
 The details of the study have been provided to me in writing and explained to me in 
my own language. 
 I confirm that I have understood the above study and had the opportunity to ask 
questions. 
 I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. 
 I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
 I have been given an information sheet giving details of the study. 
 I fully consent to participate in the above study.  
 
            Signature of investigator       Signature of participant/parent 
 
                      ய ஒ~©த கத 
கிைளேகாசிேலச} ேகாளா¯tகான ம¯{¢வ அறிறிக உள 
ேநாயாளய} இர{த{தி ரா}ெபƬ} எ§ ©ரத{தி} 
கிைளேகாசிேலச} எவா² உள¢ எ}பைத கzடறி­ ஆº 
பuேகபவ¾} ெபய   :   
பuேகபவ¾} எz: 
 ேமேல றி~பyள ம¯{¢வ ஆவ} வவரuக எனt ெதளவாக 
வளtக~பyட¢.எ}§ைடய ச|ேதகuகைள ேகyகº, அதகான த|த 
வளtகuகைள ெபறº வாபளtக~பyட¢. 
 நா} இ|த ஆவ த}னvைசயாக பuேககிேற}. எ|த கyட{தி´  நா} 
இ|த ஆவ இ¯|¢ வலகி ெகாளலா எ}² அறி|¢ ெகாzேட},      
 இ|த ஆவ} ¬ல கிைடt தகவகைள­, ப¾ேசாதைன 
«ºகைள­ ம² சிகிvைச ெதாடபான தகவகைள­ ம¯{¢வ 
ேமெகா¶ ஆவ பய}ப{தி ெகாளº அைத பர¾tகº எ} 
«¸ மன¢ட} சமதிtகிேற}  
 இ|த ஆவ எனt இர{த~ ப¾ேசாதைன ெச¢ெகாள «¸ மன¢ட} 
சமதிtகிேற} 
 இத} ¬ல எ|த  ப}வைளº வரா¢ என ம¯{¢வ ¬ல ெத¾|¢ 
ெகாz எ}§ைடய யநிைனºட} ம² «¸ த|திர{¢ட} இ|த 
ம¯{¢வ ஆராvசிய எ}ைன ேச{¢tெகாள சமதிtகிேற}           .                                         
       
பuேகபாள ைகெயா~ப  ...........................இட......................ேததி 
கyைடவர ேரைக 
 
பÕேகäபாளß/ெபேறா  ெபயß மä²Ý லாசÝ..................................................  
ஆராÞÖzயாளß ைகெயாÜபÝ .........................இட.........................ேததி                    
 
  
ஆராvசி தகவ  தா 
ெந¯ஙகிய இர{த உறº தி¯மணuக¶ அதனா ஏப பறவ 
ேகாளா²க¶ ந நாy பரவலாக உள¢.கிைளேகாசிேலச} ேகாளா² 
எ§ பறவ ேநாய ேநாயாளய} திவ´ இர{தததி´ உள 
பலவைகயான ©ரத«, ெகா¸~© அமிலuக¶ கிைளேகாசிேலச} 
ைறபாட} உளன. இதனா பலவைகயான வவƬtக «யாத 
நரபய ம² நரபய அலாத பாதி~©க  ஏபகி}ற¢. எனேவ 
இ{தைகய கிைளேகாசிேலச} ேகாளா¯tகான ம¯{¢வ அறிறிக உள 
ேநாயாளய} இர{த{தி ரா}ெபƬ} எ§ ©ரத{தி} 
கிைளேகாசிேலச} எவா² உள¢ எ}பைத கzடறி­ ஆº 
ேமெகாள~பகிற¢. இ|த ஆவ பறவ கிைளேகாசிேலச} 
ேகாளா²tகான ம¯{¢வ அறிறிகைள உள ேநாயாளய} இர{த{தி 3 
மி.லி  இர{த எ{¢ ஆராvசிt உyப{த உேள}. 
              இ|த ஆராvசிய  உuக¶ைடய இர{த சில  சிற~©~ ப¾ேசாதைனக¶t 
உyப{த~ப.  அதனா  தuகள¢  ேநாய} ஆவறிtைகேயா 
அல¢  சிகிvைசேயா பாதி~©t உளாகா¢ எ}பைத­ ெத¾வ{¢t 
ெகாகிேறா. 
              இ|த ஆராvசிய} «ºகைள அல¢ க¯{¢tகைள ெவளய ேபாேதா     
அல¢ ஆராvசிய} ேபாேதா தuகள¢ ெபயைரேயா அல¢ 
அைடயாளuகைளேயா ெவளயடமாyேடா எ}பைத­ ெத¾வ{¢t 
ெகாகிேறா. 
          இ|த ஆராvசிய பuேகப¢ தuக¶ைடய வ¯~ப{தி}  ேப¾ தா} 
இ¯tகிற¢.ேம´  நuக எ|ேநர« இ|த ஆராvசியலி¯ |¢ ப}வாuகலா 
எ}பைத­ ெத¾வ{¢ெகாகிேறா. 
      இ|த சிற~© ப¾ேசாதைனகள} «ºகைள ஆராvசிய} 
ேபா¢  அல¢ஆராvசிய} «வ}  ேபா¢ தuக¶t அறிவ~ேபா 
எ}பைத­ ெத¾வ{¢tெகாகிேறா 
 
ஆராvசியாள ைகெயா~ப                       
 
 
 
 
பuேகபாள /ெபேறா 
ைகெயா~ப   
ேததி:  
  
  
 
